

# Steven R Feldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2437716/publications.pdf>

Version: 2024-02-01

1,092  
papers

37,702  
citations

5268

83  
h-index

5829

161  
g-index

1116  
all docs

1116  
docs citations

1116  
times ranked

20703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Psoriasis causes as much disability as other major medical diseases. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 401-407.	1.2	1,325
2	Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. <i>JAMA Dermatology</i> , 2015, 151, 1081.	4.1	1,290
3	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 826-850.	1.2	1,128
4	Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006. <i>Archives of Dermatology</i> , 2010, 146, 283-7.	1.4	1,017
5	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 116-132.	1.2	970
6	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 338-351.	1.2	889
7	Guidelines of care for the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 327-349.	1.2	695
8	Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2004, 9, 136-139.	0.8	618
9	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 451-485.	1.2	505
10	Epidemiology of psoriatic arthritis in the population of the United States. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 573.e1-573.e13.	1.2	499
11	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 851-864.	1.2	456
12	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 31.e1-31.e15.	1.2	444
13	Skin cancer is among the most costly of all cancers to treat for the Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 425-429.	1.2	438
14	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 643-659.	1.2	419
15	The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society. <i>Pediatric Dermatology</i> , 2005, 22, 192-199.	0.9	408
16	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 137-174.	1.2	398
17	Psoriasis assessment tools in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii65-ii68.	0.9	359
18	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 114-135.	1.2	311

#	ARTICLE	IF	CITATIONS
19	Determinants of quality of life in patients with psoriasis: A study from the US population. Journal of the American Academy of Dermatology, 2004, 51, 704-708.	1.2	305
20	Acne vulgaris. Nature Reviews Disease Primers, 2015, 1, 15029.	30.5	258
21	Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology, 2014, 71, 1218-1233.	1.2	256
22	Quality of life in patients with psoriasis. Health and Quality of Life Outcomes, 2006, 4, 35.	2.4	253
23	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 2015, 173, 949-961.	1.5	253
24	The prevalence of psoriasis in African Americans: Results from a population-based study. Journal of the American Academy of Dermatology, 2005, 52, 23-26.	1.2	250
25	A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 859-866.	1.2	249
26	The Self-Administered Psoriasis Area and Severity Index Is Valid and Reliable. Journal of Investigative Dermatology, 1996, 106, 183-186.	0.7	241
27	Stealth monitoring of adherence to topical medication: Adherence is very poor in children with atopic dermatitis. Journal of the American Academy of Dermatology, 2007, 56, 211-216.	1.2	237
28	Two considerations for patients with psoriasis and their clinicians:. Journal of the American Academy of Dermatology, 2000, 43, 281-285.	1.2	218
29	Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. Journal of the American Academy of Dermatology, 2005, 52, 425-433.	1.2	216
30	Development and validation of a health-related quality of life instrument for women with melasma. British Journal of Dermatology, 2003, 149, 572-577.	1.5	202
31	Pyoderma gangrenosum: A review and update on new therapies. Journal of the American Academy of Dermatology, 2010, 62, 646-654.	1.2	197
32	Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. Journal of the American Academy of Dermatology, 2004, 51, 212-216.	1.2	181
33	Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. Journal of the American Academy of Dermatology, 2010, 63, 457-465.	1.2	180
34	Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. Journal of the American Academy of Dermatology, 2002, 46, 900-906.	1.2	178
35	Combination therapy to treat moderate to severe psoriasis. Journal of the American Academy of Dermatology, 2004, 50, 416-430.	1.2	178
36	Adherence to topical therapy increases around the time of office visits. Journal of the American Academy of Dermatology, 2007, 57, 81-83.	1.2	173

#	ARTICLE	IF	CITATIONS
37	The 5-point Investigatorâ€™s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. <i>Journal of Dermatological Treatment</i> , 2015, 26, 23-31.	2.2	173
38	Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 45-51.	1.2	171
39	Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 709-711.	1.2	171
40	Cost of Nonmelanoma Skin Cancer Treatment in the United States. <i>Dermatologic Surgery</i> , 2001, 27, 1035-1038.	0.8	168
41	Tacrolimus ointment is effective for facial and intertriginous psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 723-730.	1.2	166
42	Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 821-838.	6.7	159
43	The economic impact of psoriasis increases with psoriasis severity. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 564-569.	1.2	156
44	Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95.	1.4	148
45	Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 271-275.	1.2	143
46	Psoriasis: Improving adherence to topical therapy. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 1009-1016.	1.2	141
47	The Safety of Liposuction: Results of a National Survey. <i>Dermatologic Surgery</i> , 2002, 28, 971-978.	0.8	137
48	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€”based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
49	Interleukin-12, interleukin-23, and psoriasis: Current prospects. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 1059-1068.	1.2	135
50	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 841-850.	1.2	135
51	A review of phototherapy protocols for psoriasis treatment. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 936-949.	1.2	128
52	Better medication adherence results in greater improvement in severity of psoriasis. <i>British Journal of Dermatology</i> , 2004, 151, 895-897.	1.5	127
53	Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. <i>Journal of Dermatological Treatment</i> , 2018, 29, 13-18.	2.2	127
54	Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. <i>British Journal of Dermatology</i> , 2005, 152, 954-960.	1.5	124

#	ARTICLE	IF	CITATIONS
55	Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2494-2500.	1.9	120
56	The effect of reminder systems on patients' adherence to treatment. <i>Patient Preference and Adherence</i> , 2012, 6, 127.	1.8	118
57	The Physical, Psychological and Social Impact of Psoriasis. <i>Journal of Health Psychology</i> , 1997, 2, 525-537.	2.3	116
58	The psychological impact of rosacea and the influence of current management options. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 973-980.	1.2	115
59	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016, 39, 755-762.	3.2	112
60	Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1483-1503.	1.8	109
61	Lifestyle high-risk behaviors and demographics may predict the level of participation in sun-protection behaviors and skin cancer primary prevention in the united states. <i>Cancer</i> , 2001, 92, 1315-1324.	4.1	107
62	Prevalence and relevance of contact dermatitis allergens: A meta-analysis of 15 years of published T.R.U.E. test data. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 349-353.	1.2	106
63	Topical drug delivery systems in dermatology: a review of patient adherence issues. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 1263-1271.	5.0	105
64	The comorbid state of psoriasis patients in a university dermatology practice. <i>Journal of Dermatological Treatment</i> , 2005, 16, 319-323.	2.2	104
65	Anger and acne: implications for quality of life, patient satisfaction and clinical care. <i>British Journal of Dermatology</i> , 2004, 151, 183-189.	1.5	102
66	Clearance is not a realistic expectation of psoriasis treatment. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 796-802.	1.2	101
67	Research gaps in psoriasis: Opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 146-167.	1.2	101
68	Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 434-444.	1.2	100
69	Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2004, 150, 317-326.	1.5	99
70	The Economic Impact of Non-Melanoma Skin Cancer: A Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 888-896.	4.9	99
71	Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 217-220.	1.2	98
72	Factors affecting sleep quality in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 114-123.	1.2	97

#	ARTICLE	IF	CITATIONS
73	Psoriasis and Pregnancy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 561-570.	1.2	94
74	Seasonal variation of dermatologic disease in the USA: a study of office visits from 1990 to 1998. <i>International Journal of Dermatology</i> , 2004, 43, 6-11.	1.0	93
75	American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. <i>Journal of the American Academy of Dermatology</i> , 2004, 50, 900-906.	1.2	93
76	The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. <i>British Journal of Dermatology</i> , 2015, 172, 1487-1497.	1.5	91
77	Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation.. <i>Health Psychology</i> , 1998, 17, 530-536.	1.6	89
78	Disease Severity Measures in a Population of Psoriasis Patients: The Symptoms of Psoriasis Correlate With Self-Administered Psoriasis Area Severity Index Scores. <i>Journal of Investigative Dermatology</i> , 1996, 107, 26-29.	0.7	88
79	Acne vulgaris and depression: a retrospective examination. <i>Journal of Cosmetic Dermatology</i> , 2010, 9, 59-63.	1.6	88
80	Electrosurgery. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 591.e1-591.e14.	1.2	88
81	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2â€”Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	1.2	88
82	Adult pityriasis rubra pilaris: A 10-year case series. <i>Journal of the American Academy of Dermatology</i> , 1997, 36, 959-964.	1.2	87
83	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2009, 219, 209-218.	2.1	87
84	Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. <i>British Journal of Dermatology</i> , 2002, 147, 1192-1198.	1.5	86
85	Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. <i>Cutis</i> , 2011, 87, 201-7.	0.3	86
86	Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2555-2562.	1.8	85
87	The negative impact of psoriasis on the workplace. <i>Journal of Dermatological Treatment</i> , 2006, 17, 24-28.	2.2	84
88	Frequency and Cost of Actinic Keratosis Treatment. <i>Dermatologic Surgery</i> , 2006, 32, 1045-1049.	0.8	83
89	Patient Measurement of Psoriasis Disease Severity with a Structured Instrument. <i>Journal of Investigative Dermatology</i> , 1994, 102, 967-969.	0.7	82
90	A quantitative definition of severe psoriasis for use in clinical trials. <i>Journal of Dermatological Treatment</i> , 2004, 15, 27-29.	2.2	81

#	ARTICLE	IF	CITATIONS
91	Translating Atopic Dermatitis Management Guidelines Into Practice for Primary Care Providers. <i>Pediatrics</i> , 2015, 136, 554-565.	2.1	78
92	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
93	Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 887-889.	1.2	77
94	Melasma and its impact on health-related quality of life in Hispanic women. <i>Journal of Dermatological Treatment</i> , 2007, 18, 5-9.	2.2	77
95	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016, 16, 15.	2.1	77
96	Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2008, 159, 704-710.	1.5	76
97	Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 125-135.	1.2	76
98	New and Emerging Systemic Treatments for Atopic Dermatitis. <i>Drugs</i> , 2020, 80, 1041-1052.	10.9	76
99	Correlates of health-related quality of life in women with severe facial blemishes. <i>International Journal of Dermatology</i> , 2006, 45, 111-115.	1.0	75
100	The prevalence of melasma and its association with quality of life in adult male Latino migrant workers. <i>International Journal of Dermatology</i> , 2009, 48, 22-26.	1.0	75
101	Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2018, 154, 903.	4.1	75
102	Acne vulgaris in the United States: a descriptive epidemiology. <i>Cutis</i> , 2010, 86, 94-9.	0.3	75
103	Most Common Dermatologic Problems Identified by Internists, 1990-1994. <i>Archives of Internal Medicine</i> , 1998, 158, 726.	3.8	73
104	Economic evaluation of systemic therapies for moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1264-1272.	1.5	73
105	Health Care Utilization in Patients With Migraine: Demographics and Patterns of Care in the Ambulatory Setting. <i>Headache</i> , 2003, 43, 330-335.	3.9	72
106	Electronic monitoring of medication adherence in skin disease: Results of a pilot study. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 651-654.	1.2	72
107	Decision points for the initiation of systemic treatment for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 101-107.	1.2	72
108	Oral Griseofulvin Remains the Treatment of Choice for Tinea Capitis in Children. <i>Pediatric Dermatology</i> , 2000, 17, 304-309.	0.9	71

#	ARTICLE	IF	CITATIONS
109	Topical Retinoids in Acne Vulgaris: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 345-365.	6.7	71
110	Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. <i>Cutis</i> , 2002, 70, 327-32.	0.3	71
111	Destructive procedures are the standard of care for treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 43-47.	1.2	69
112	Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study. <i>Journal of Cosmetic Dermatology</i> , 2008, 7, 164-168.	1.6	68
113	Incidence, Risk Factors, and Preventative Management of Skin Cancers in Organ Transplant Recipients: A Review of Single- and Multicenter Retrospective Studies from 2006 to 2010. <i>Dermatologic Surgery</i> , 2013, 39, 345-364.	0.8	68
114	Real-world burden of comorbidities in US patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 287-292.e4.	1.2	68
115	The specialty of the treating physician affects the likelihood of tumor-free resection margins for basal cell carcinoma: Results from a multi-institutional retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 224-230.	1.2	67
116	Patients' Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 221-224.	6.7	67
117	Pruritus in adult dermatomyositis. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 273-276.	1.3	67
118	Adherence in dermatology: A review of the last 20 years. <i>Journal of Dermatological Treatment</i> , 2006, 17, 136-142.	2.2	67
119	Use of electronic medical records differs by specialty and office settings. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, e33-e38.	4.4	67
120	The SAPASI Is Valid and Responsive to Psoriasis Disease Severity Changes in a Multi-Center Clinical Trial. <i>Journal of Dermatology</i> , 1999, 26, 210-215.	1.2	65
121	Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 294-301.	2.2	65
122	Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. <i>British Journal of Dermatology</i> , 2017, 176, 759-764.	1.5	65
123	Alternative therapies commonly used within a population of patients with psoriasis. <i>Cutis</i> , 1996, 58, 216-20.	0.3	65
124	Top dermatologic conditions in patients of color: an analysis of nationally representative data. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 466-73.	0.8	65
125	Binding of IgA2-macroglobulin to hepatocytes: Mechanism of in vivo clearance. <i>Biochemical and Biophysical Research Communications</i> , 1985, 128, 795-802.	2.1	64
126	Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2006, 32, 1473-1479.	0.8	64



#	ARTICLE	IF	CITATIONS
127	Treatment Patterns and Cost of Nonmelanoma Skin Cancer Management. <i>Dermatologic Surgery</i> , 2006, 32, 1266-1271.	0.8	64
128	The economic burden of psoriasis: a systematic literature review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 685-705.	1.4	64
129	Statistical Significance and Clinical Relevance. <i>Archives of Dermatology</i> , 2004, 140, 1520-3.	1.4	63
130	Pharmacoeconomic Considerations in Treating Actinic Keratosis. <i>Pharmacoeconomics</i> , 2009, 27, 451-464.	3.3	62
131	Ultraviolet phototherapy for cutaneous diseases: a concise review. <i>Oral Diseases</i> , 2016, 22, 253-259.	3.0	62
132	Members of the National Psoriasis Foundation. <i>Archives of Dermatology</i> , 2005, 141, 19-26.	1.4	61
133	Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, S235-S236.	1.2	61
134	Tanning as an addictive behavior: a literature review. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 12-19.	1.5	61
135	A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2018, 179, 1062-1071.	1.5	61
136	Written action plans: Potential for improving outcomes in children with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 677-683.	1.2	59
137	Psoriasis, Depression, and Inflammatory Overlap: A Review. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 613-620.	6.7	59
138	Epidemiology of mental health comorbidity in psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 487-495.	2.2	59
139	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1525-1533.	1.8	58
140	Definitions of Measures of Effect Duration for Psoriasis Treatments. <i>Archives of Dermatology</i> , 2005, 141, 82-4.	1.4	58
141	The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. <i>American Health and Drug Benefits</i> , 2016, 9, 504-513.	0.5	58
142	Phototherapy utilization for psoriasis is declining in the United States. <i>Journal of the American Academy of Dermatology</i> , 2002, 46, 557-559.	1.2	57
143	Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2015, 4, 231-242.	2.4	57
144	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1162-1170.e3.	1.2	57

#	ARTICLE	IF	CITATIONS
145	Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. <i>Cutis</i> , 2010, 86, 103-8.	0.3	57
146	Psoriasis and Pregnancy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 561-570.	1.2	56
147	Conversations on psoriasis – what patients want and what physicians can provide: A qualitative look at patient and physician expectations. <i>Journal of Dermatological Treatment</i> , 2010, 21, 6-12.	2.2	56
148	A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2041-2054.	1.8	56
149	Should patients stop their biologic treatment during the COVID-19 pandemic. <i>Journal of Dermatological Treatment</i> , 2020, 31, 317-318.	2.2	56
150	Efficacy, Safety, and Cost of Office-Based Surgery. <i>Dermatologic Surgery</i> , 2003, 29, 1-6.	0.8	55
151	The Safety of Office-Based Surgery. <i>Archives of Dermatology</i> , 2004, 140, 1379-82.	1.4	55
152	Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 315-326.	6.7	55
153	Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 201-209.	0.9	55
154	Rosacea Management. <i>Skin Appendage Disorders</i> , 2016, 2, 26-34.	1.0	55
155	Î±2-macroglobulin –fast™ forms inhibit superoxide production by activated macrophages. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1983, 760, 421-423.	2.4	54
156	Office-Based Physician Services Provided by Dermatologist in the United States in 1990. <i>Journal of Investigative Dermatology</i> , 1994, 102, 93-97.	0.7	54
157	Off-label prescribing in the treatment of dermatologic disease. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 217-223.	1.2	54
158	Poor Adherence to Treatments. <i>Archives of Dermatology</i> , 2007, 143, 912-5.	1.4	54
159	Medical Adherence to Acne Therapy: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 87-94.	6.7	54
160	An assessment of the use of antihistamines in the management of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 92-96.	1.2	54
161	Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. <i>Clinics in Dermatology</i> , 2019, 37, 160-166.	1.6	54
162	Treatment of Psoriasis in Children: Is There a Role for Antibiotic Therapy and Tonsillectomy?. <i>Pediatric Dermatology</i> , 2003, 20, 11-15.	0.9	53

#	ARTICLE	IF	CITATIONS
163	Frequency of Primary Nonadherence to Acne Treatment. <i>JAMA Dermatology</i> , 2015, 151, 623.	4.1	53
164	Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients with Comorbid Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 708-717.	3.4	53
165	Comparison of the binding of chicken $\hat{1}$ -macroglobulin and ovomacroglobulin to the mammalian $\hat{2}$ -macroglobulin receptor. <i>Archives of Biochemistry and Biophysics</i> , 1984, 235, 267-275.	3.0	52
166	In vivo catabolism of $\hat{1}$ -antichymotrypsin is mediated by the Serpin receptor which binds $\hat{1}$ -proteinase inhibitor, antithrombin III and heparin cofactor II. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1988, 967, 158-162.	2.4	52
167	Disease severity and associated family impact in childhood atopic dermatitis. <i>Archives of Disease in Childhood</i> , 2003, 88, 423-427.	1.9	52
168	Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment. <i>Archives of Dermatology</i> , 2005, 141, 43-6.	1.4	52
169	Comparative Efficacy of Biologics in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 365-374.	6.7	52
170	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 102-110.	1.2	52
171	A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. <i>International Journal of Dermatology</i> , 2002, 41, 269-274.	1.0	50
172	What Is the Best Approach to Reducing Birth Defects Associated with Isotretinoin?. <i>PLoS Medicine</i> , 2006, 3, e483.	8.4	50
173	The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12793.	4.1	50
174	Adherence in dermatology. <i>Journal of Dermatological Treatment</i> , 2017, 28, 94-103.	2.2	49
175	Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 253-271.	6.7	49
176	Involving the patient: Impact of inflammatory skin disease and patient-focused care. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, S78-S85.	1.2	48
177	Alopecia in the United States: Outpatient utilization and common prescribing patterns. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, S49-S51.	1.2	48
178	Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2017, 28, 591-599.	2.2	48
179	The cost of biologics for psoriasis is increasing. <i>Drugs in Context</i> , 2014, 3, 1-10.	2.2	48
180	Diagnosis and treatment of acne. <i>American Family Physician</i> , 2004, 69, 2123-30.	0.1	48

#	ARTICLE	IF	CITATIONS
181	How good are US dermatologists at discriminating skin cancers? A number-needed-to-treat analysis. <i>Journal of Dermatological Treatment</i> , 2012, 23, 65-69.	2.2	47
182	Commercial Tanning Bed Treatment Is an Effective Psoriasis Treatment: Results from an Uncontrolled Clinical Trial. <i>Journal of Investigative Dermatology</i> , 1997, 109, 170-174.	0.7	46
183	Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 874-888.	0.9	46
184	In vitro binding and in vivo clearance of human $\text{I}\kappa\text{B}$ -macroglobulin after reaction with endoproteases from four different classes. <i>Biochemical and Biophysical Research Communications</i> , 1983, 114, 757-762.	2.1	45
185	Incidence Rates, Costs, Severity, and Work-Related Factors of Occupational Dermatitis. <i>Archives of Dermatology</i> , 2005, 141, 713-8.	1.4	45
186	Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?. <i>Clinics in Dermatology</i> , 2006, 24, 229-230.	1.6	45
187	Low-Dose Acitretin Is Associated With Fewer Adverse Events Than High-Dose Acitretin in the Treatment of Psoriasis. <i>Archives of Dermatology</i> , 2006, 142, 1000-4.	1.4	45
188	Topical Clobetasol Propionate in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 397-406.	6.7	45
189	Accountability: a missing construct in models of adherence behavior and in clinical practice. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1285-1294.	1.8	45
190	New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. <i>International Journal of Dermatology</i> , 2000, 39, 41-44.	1.0	44
191	The Family Impact of Atopic Dermatitis in Children: The Role of the Parent Caregiver. <i>Pediatric Dermatology</i> , 2003, 20, 5-10.	0.9	44
192	Quality of Life Measures for Acne Patients. <i>Dermatologic Clinics</i> , 2012, 30, 293-300.	1.7	44
193	Increasing Adherence with Topical Agents for Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 323-332.	6.7	44
194	Barriers to treatment: describing them from a different perspective. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 129-133.	1.8	44
195	Side effects of common acne treatments. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 39-51.	2.4	43
196	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	1.2	43
197	Tobacco smoking contributes little to facial wrinkling. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 12, 133-139.	2.4	42
198	Correlates of patient satisfaction with physician visit: Differences between elderly and non-elderly survey respondents. <i>Health and Quality of Life Outcomes</i> , 2007, 5, 62.	2.4	42

#	ARTICLE	IF	CITATIONS
199	A review of targeted ultraviolet B phototherapy for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 664-672.	1.2	42
200	Electrosurgery. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 607.e1-607.e12.	1.2	42
201	The Acne Quality of Life Index (Acne-QOLI). <i>American Journal of Clinical Dermatology</i> , 2006, 7, 185-192.	6.7	41
202	Green tobacco sickness and skin integrity among migrant latino farmworkers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 195-203.	2.1	41
203	Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 285-294.	6.7	41
204	Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. <i>BMC Health Services Research</i> , 2017, 17, 337.	2.2	41
205	Novel combination regimens: Biologics and acitretin for the treatment of psoriasis – a case series. <i>Journal of Dermatological Treatment</i> , 2006, 17, 86-89.	2.2	40
206	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study. <i>Health and Quality of Life Outcomes</i> , 2008, 6, 75.	2.4	40
207	Emerging drugs for the treatment of acne. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 91-101.	2.4	40
208	Treating Skin Disease. <i>Journal of Agromedicine</i> , 2006, 11, 27-35.	1.5	39
209	Vitamin E and Allergic Contact Dermatitis. <i>Dermatitis</i> , 2010, 21, 148-153.	1.6	39
210	Assessing adherence to dermatology treatments: a review of self-report and electronic measures. <i>Skin Research and Technology</i> , 2010, 16, 253-258.	1.6	39
211	Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2019, 25, 479-488.	0.9	39
212	Procedures for skin diseases performed by physicians in 1993 and 1994: Analysis of data from the National Ambulatory Medical Care Survey. <i>Journal of the American Academy of Dermatology</i> , 1997, 37, 719-724.	1.2	38
213	Tanning and Skin Cancer. <i>Pediatric Dermatology</i> , 2005, 22, 501-512.	0.9	38
214	The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. <i>Journal of Dermatological Treatment</i> , 2006, 17, 29-37.	2.2	38
215	Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review. <i>Journal of Dermatological Treatment</i> , 2007, 18, 223-242.	2.2	38
216	Ultraviolet Tanning Addiction. <i>Dermatologic Clinics</i> , 2009, 27, 109-112.	1.7	38

#	ARTICLE	IF	CITATIONS
217	A Randomized Controlled Pilot Study of the Effects of an Extra Office Visit on Adherence and Outcomes in Atopic Dermatitis. Archives of Dermatology, 2010, 146, 1428.	1.4	38
218	Understanding and Improving Treatment Adherence in Pediatric Patients. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 137-140.	1.6	38
219	Adherence in Atopic Dermatitis. Advances in Experimental Medicine and Biology, 2017, 1027, 139-159.	1.6	38
220	Adherence to a Topical Regimen of 5-Fluorouracil, 0.5%, Cream for the Treatment of Actinic Keratoses. Archives of Dermatology, 2009, 145, 203-5.	1.4	37
221	An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. Journal of the American Academy of Dermatology, 2009, 60, 879-880.	1.2	37
222	Medication Adherence, Healthcare Costs and Utilization Associated with Acne Drugs in Medicaid Enrollees with Acne Vulgaris. American Journal of Clinical Dermatology, 2013, 14, 243-251.	6.7	37
223	Trends in Sunscreen Recommendation Among US Physicians. JAMA Dermatology, 2014, 150, 51.	4.1	37
224	Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation.. Health Psychology, 1998, 17, 530-536.	1.6	37
225	Surgical Treatment of Nonmelanoma Skin Cancer in the Medicare Population. Dermatologic Surgery, 2003, 29, 1167-1169.	0.8	36
226	The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Seminars in Cutaneous Medicine and Surgery, 2005, 24, 52-57.	1.6	36
227	Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opinion on Pharmacotherapy, 2006, 7, 157-167.	1.8	36
228	A Review of Adapalene in the Treatment of Acne Vulgaris. Journal of Adolescent Health, 2008, 43, 421-424.	2.5	36
229	A randomized controlled pilot study of strategies to increase adherence in teenagers with acne vulgaris. Journal of the American Academy of Dermatology, 2011, 64, 793-795.	1.2	36
230	New developments in the treatment of rosacea &ndash; role of once-daily ivermectin cream. Clinical, Cosmetic and Investigational Dermatology, 2016, 9, 71.	1.8	36
231	Rosacea Patient Perspectives on Homeopathic and Over-the-counter Therapies. Journal of Clinical and Aesthetic Dermatology, 2015, 8, 30-4.	0.1	36
232	Nonmelanoma Skin Cancer: An Episode of Care Management Approach. Dermatologic Surgery, 2003, 29, 700-711.	0.8	35
233	The economic burden of skin disease in the United States. Journal of the American Academy of Dermatology, 2003, 48, 592-599.	1.2	35
234	Are there racial and sex differences in the use of oral isotretinoin for acne management in the United States?. Journal of the American Academy of Dermatology, 2003, 49, 662-666.	1.2	35

#	ARTICLE	IF	CITATIONS
235	The Skinny on Psoriasis and Obesity. Archives of Dermatology, 2005, 141, 1601-2.	1.4	35
236	Psoriasis treatment in the United States at the end of the 20th century. International Journal of Dermatology, 2006, 45, 370-374.	1.0	35
237	What Specialties Perform the Most Common Outpatient Cosmetic Procedures in the United States?. Dermatologic Surgery, 2008, 34, 1-8.	0.8	35
238	The Relationship Between Physician-Friendliness and Caring, and Patient Satisfaction. Patient, 2008, 1, 91-96.	2.7	35
239	Interventions to increase adherence to acne treatment. Patient Preference and Adherence, 2016, Volume 10, 2091-2096.	1.8	35
240	Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clinical Therapeutics, 1999, 21, 1725-1731.	2.5	34
241	Skin Disease in Children: Effects on Quality of Life, Stigmatization, Bullying, and Suicide Risk in Pediatric Acne, Atopic Dermatitis, and Psoriasis Patients. Children, 2021, 8, 1057.	1.5	34
242	Why Are There Differences in the Perceived Safety of Office-Based Surgery?. Dermatologic Surgery, 2004, 30, 1377-1379.	0.8	33
243	Development and validation of the Dermatomyositis Skin Severity Index. British Journal of Dermatology, 2008, 158, 345-350.	1.5	33
244	Impact and management of depression in psoriasis patients. Expert Opinion on Pharmacotherapy, 2016, 17, 147-152.	1.8	33
245	Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. Journal of Medical Economics, 2017, 20, 982-990.	2.1	33
246	Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments. Journal of the American Academy of Dermatology, 2007, 57, 972-976.	1.2	32
247	Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. Journal of the American Academy of Dermatology, 2008, 59, 577-581.	1.2	32
248	Effect of patient satisfaction on outcomes of care. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 393-395.	1.4	32
249	The Role of Tetracyclines in Rosacea. American Journal of Clinical Dermatology, 2010, 11, 79-87.	6.7	32
250	An Internet-Based Survey and Improvement of Acne Treatment Outcomes. Archives of Dermatology, 2011, 147, 1223.	1.4	32
251	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. Journal of Dermatological Treatment, 2011, 22, 65-74.	2.2	32
252	To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2015, 73, 420-428.e1.	1.2	32

#	ARTICLE	IF	CITATIONS
253	A guide to prescribing home phototherapy for patients with psoriasis: The appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 868-878.e1.	1.2	32
254	Web App- and Text Message-Based Patient Education in Mohs Micrographic Surgery—A Randomized Controlled Trial. <i>Dermatologic Surgery</i> , 2018, 44, 924-932.	0.8	32
255	Current treatment options for acanthosis nigricans. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 407-413.	1.8	32
256	The most common causes of burnout among US academic dermatologists based on a survey study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 269-270.	1.2	32
257	Clinical Diagnosis of Actinic Keratosis Identifies an Elderly Population at High Risk of Developing Skin Cancer. <i>Dermatologic Surgery</i> , 2005, 31, 43-47.	0.8	31
258	Health Care Utilization Among Migrant Latino Farmworkers: The Case of Skin Disease. <i>Journal of Rural Health</i> , 2009, 25, 98-103.	2.9	31
259	The efficacy of adapalene-benzoyl peroxide combination increases with number of acne lesions. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1085-1091.	1.2	31
260	Biologics and biosimilars. <i>Journal of Dermatological Treatment</i> , 2015, 26, 299-302.	2.2	31
261	Current challenges and emerging drug delivery strategies for the treatment of psoriasis. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1461-1473.	5.0	31
262	Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A Propensity-Matched Case Control Study. <i>Dermatology and Therapy</i> , 2016, 6, 649-658.	3.0	31
263	Recommendations for phototherapy during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 287-288.	1.2	31
264	Vitamin D analogue-based therapies for psoriasis. <i>Drugs of Today</i> , 2010, 46, 351.	1.1	31
265	A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. <i>Dermatology Online Journal</i> , 2014, 20, 22608.	0.5	31
266	Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: An analysis of the National Ambulatory Medical Care Survey, 1990–1994. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 221-226.	1.2	30
267	THE MAGNITUDE OF SKIN DISEASE IN THE UNITED STATES. <i>Dermatologic Clinics</i> , 2000, 18, xv-xxi.	1.7	30
268	Medication adherence among acne patients: a review. <i>Journal of Cosmetic Dermatology</i> , 2010, 9, 160-166.	1.6	30
269	Changing Age of Acne Vulgaris Visits: Another Sign of Earlier Puberty?. <i>Pediatric Dermatology</i> , 2011, 28, 645-648.	0.9	30
270	Trends in Pediatric Psoriasis Outpatient Health Care Delivery in the United States. <i>Archives of Dermatology</i> , 2012, 148, 66.	1.4	30



#	ARTICLE	IF	CITATIONS
271	Assessment of rosacea severity: A review of evaluation methods used in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 138-143.e4.	1.2	30
272	Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary. <i>Journal of Dermatological Treatment</i> , 2016, 27, 322-327.	2.2	30
273	Relative efficacy of systemic treatments for atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 411-416.e4.	1.2	30
274	&lt;p&gt;Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 255-272.	5.8	30
275	The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. <i>British Journal of Dermatology</i> , 2005, 152, 382-383.	1.5	29
276	Social Sensitivity and ACNE: The Role of Personality in Negative Social Consequences and Quality of Life. <i>International Journal of Psychiatry in Medicine</i> , 2006, 36, 121-130.	1.8	29
277	Pachydermodactyly From Repetitive Motion in Poultry Processing Workers. <i>Archives of Dermatology</i> , 2012, 148, 925-8.	1.4	29
278	Use of topical antibiotics as prophylaxis in clean dermatologic procedures. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 445-451.e3.	1.2	29
279	Trends in Mohs Surgery From 1995 to 2010. <i>Dermatologic Surgery</i> , 2015, 41, 397-403.	0.8	29
280	Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. <i>Journal of Dermatological Treatment</i> , 2018, 29, 769-774.	2.2	29
281	Trends in the Use of Neurotoxins and Dermal Fillers by US Physicians. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 14-9.	0.1	29
282	Sex-specific differences in the treatment of severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 620-623.	1.2	28
283	Demographics of aging and skin disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 631-641.	2.6	28
284	Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 39-43.	1.2	28
285	Patient Demographics and Utilization of Health Care Services for Molluscum Contagiosum. <i>Pediatric Dermatology</i> , 2004, 21, 628-632.	0.9	28
286	To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 970-977.	1.2	28
287	Vision Problems, Eye Care History, and Ocular Protection Among Migrant Farmworkers. <i>Archives of Environmental and Occupational Health</i> , 2008, 63, 13-16.	1.4	28
288	Calcitriol ointment: A review of a topical vitamin D analog for psoriasis. <i>Journal of Dermatological Treatment</i> , 2009, 20, 208-212.	2.2	28

#	ARTICLE	IF	CITATIONS
289	Recruiting underserved populations to dermatologic research: a systematic review. <i>International Journal of Dermatology</i> , 2011, 50, 385-395.	1.0	28
290	Risk of Cardiovascular Disorders in Psoriasis Patients. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 1-7.	6.7	28
291	Management of Keloids in the United States, 1990–2009: An Analysis of the National Ambulatory Medical Care Survey. <i>Dermatologic Surgery</i> , 2013, 39, 988-994.	0.8	28
292	Rosacea: New and Emerging Treatments. <i>Drugs</i> , 2014, 74, 1457-1465.	10.9	28
293	Psoriasis during pregnancy: characteristics and important management recommendations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 709-720.	3.0	28
294	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 498-506.	2.4	28
295	Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1017-1020.	1.2	27
296	Systemic treatment for moderate to severe psoriasis: Estimates of failure rates and direct medical costs in a north-eastern US managed care plan. <i>Journal of Dermatological Treatment</i> , 2005, 16, 37-42.	2.2	27
297	Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis. <i>Archives of Dermatology</i> , 2005, 141, 1154.	1.4	27
298	Safety and Tolerability of Tumor Necrosis Factor- $\alpha$ Inhibitors in Psoriasis: A Narrative Review. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 37-43.	6.7	27
299	Pharmacokinetics of tazarotene and acitretin in psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 919-927.	3.3	27
300	A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. <i>Dermatology Online Journal</i> , 2004, 10, 7.	0.5	27
301	Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance?. <i>Journal of Drugs in Dermatology</i> , 2010, 9, 519-24.	0.8	27
302	The cutaneous surgery experience of multiple specialties in the Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 1045-1048.	1.2	26
303	Foreword. <i>BioDrugs</i> , 2013, 27, 1-2.	4.6	26
304	Combination Therapy in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 9-25.	6.7	26
305	Tolerability of Topical Retinoids. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 530-538.	1.2	26
306	Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. <i>British Journal of Dermatology</i> , 2018, 178, e215-e216.	1.5	26

#	ARTICLE	IF	CITATIONS
307	Minimal clinically important difference (<scp>MCID</scp>) for work productivity and activity impairment (<scp>WPAI</scp>) questionnaire in psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 318-324.	2.4	26
308	Psoriasis patient preferences for topical drugs: a systematic review. Journal of Dermatological Treatment, 2021, 32, 478-483.	2.2	26
309	How patients experience and manage dryness and irritation from acne treatment. Journal of Drugs in Dermatology, 2011, 10, 605-8.	0.8	26
310	Disease burden and treatment adherence in psoriasis patients. Cutis, 2013, 92, 258-63.	0.3	26
311	Latino farmworker perceptions of the risk factors for occupational skin disease. American Journal of Industrial Medicine, 2006, 49, 434-442.	2.1	25
312	Increasing use of more potent treatments for psoriasis. Journal of the American Academy of Dermatology, 2009, 60, 478-481.	1.2	25
313	Retinoid plus antimicrobial combination treatments for acne. Clinical, Cosmetic and Investigational Dermatology, 2011, 4, 79.	1.8	25
314	The Effect of Folate Supplementation on Methotrexate Efficacy and Toxicity in Psoriasis Patients and Folic Acid Use by Dermatologists in the USA. American Journal of Clinical Dermatology, 2013, 14, 155-161.	6.7	25
315	The National Ambulatory Medical Care Survey: A resource for understanding the outpatient dermatology treatment. Journal of Dermatological Treatment, 2014, 25, 453-458.	2.2	25
316	Complementary and Alternative Medicine Use in Dermatology in the United States. Journal of Alternative and Complementary Medicine, 2014, 20, 392-398.	2.1	25
317	Betamethasone Valerate in Foam Vehicle Is Effective with Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the Treatment of Scalp Psoriasis. Journal of Cutaneous Medicine and Surgery, 2001, 5, 386-389.	1.2	24
318	Case studies in severe psoriasis: A clinical strategy. Journal of Dermatological Treatment, 2003, 14, 26-46.	2.2	24
319	Plasma $\beta$ -endorphin levels in frequent and infrequent tanners before and after ultraviolet and non-ultraviolet stimuli. Journal of the American Academy of Dermatology, 2006, 54, 919-920.	1.2	24
320	Predictors of treatment choices and associated outcomes in actinic keratoses: Results from a national physician survey study. Journal of Dermatological Treatment, 2006, 17, 162-166.	2.2	24
321	Adverse events from systemic therapies for psoriasis are common in clinical practice. Journal of Dermatological Treatment, 2006, 17, 288-293.	2.2	24
322	Physicians' perceptions of an eczema action plan for atopic dermatitis. Journal of Dermatological Treatment, 2010, 21, 28-33.	2.2	24
323	Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. Journal of Dermatological Treatment, 2011, 22, 138-143.	2.2	24
324	Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials. JAMA Dermatology, 2013, 149, 490.	4.1	24

#	ARTICLE	IF	CITATIONS
325	Hidradenitis Suppurativa Management in the United States: An Analysis of the National Ambulatory Medical Care Survey and MarketScan Medicaid Databases. <i>Skin Appendage Disorders</i> , 2015, 1, 65-73.	1.0	24
326	Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. <i>Journal of Dermatological Treatment</i> , 2016, 27, 224-227.	2.2	24
327	The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. <i>Dermatologic Therapy</i> , 2004, 17, 376-382.	1.7	23
328	The extent of dermatopathology education: A comparison of pathology and dermatology. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 694-697.	1.2	23
329	New treatments for psoriasis: Which biologic is best?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 96-107.	2.2	23
330	Open label trial of alefacept in palmoplantar pustular psoriasis. <i>Journal of Dermatological Treatment</i> , 2008, 19, 97-100.	2.2	23
331	Targeted UV therapy in the treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2008, 19, 141-145.	2.2	23
332	Quantifying and Characterizing Adverse Events in Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2013, 39, 872-878.	0.8	23
333	A Review of Patient Lifting Interventions to Reduce Health Care Worker Injuries. <i>Workplace Health and Safety</i> , 2015, 63, 267-275.	1.4	23
334	Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. <i>Journal of Dermatology &amp; Dermatologic Surgery</i> , 2016, 20, 19-26.	0.2	23
335	Emerging systemic drugs in the treatment of plaque psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 89-100.	2.4	23
336	THE EPIDEMIC OF TINEA CAPITIS DISPROPORTIONATELY AFFECTS SCHOOL-AGED AFRICAN AMERICANS. <i>Pediatric Dermatology</i> , 1999, 16, 75-75.	0.9	23
337	A review of patient adherence to topical therapies for treatment of atopic dermatitis. <i>Cutis</i> , 2015, 96, 397-401.	0.3	23
338	Circular dichroic spectroscopy of non-human Î±-macroglobulins. <i>Biochemical and Biophysical Research Communications</i> , 1984, 123, 771-777.	2.1	22
339	Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 1084-1091.	1.2	22
340	Trends in prescription of acne medication in the US: Shift from antibiotic to non-antibiotic treatment. <i>Journal of Dermatological Treatment</i> , 2005, 16, 224-228.	2.2	22
341	Differences in Acne Treatment Prescribing Patterns of Pediatricians and Dermatologists: An Analysis of Nationally Representative Data. <i>Pediatric Dermatology</i> , 2008, 25, 635-639.	0.9	22
342	Teledermatology Consultations Provide Specialty Care for Farmworkers in Rural Clinics. <i>Journal of Rural Health</i> , 2009, 25, 198-202.	2.9	22

#	ARTICLE	IF	CITATIONS
343	Treatment of Preadolescent Acne in the United States: An Analysis of Nationally Representative Data. <i>Pediatric Dermatology</i> , 2013, 30, 689-694.	0.9	22
344	Systemic Therapies for Psoriasis: An Evidence-Based Update. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 165-180.	6.7	22
345	Inflammatory diseases: Integrating biosimilars into clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, S16-S21.	3.4	22
346	Rosacea patients seeking advice: Qualitative analysis of patients'™ posts on a rosacea support forum. <i>Journal of Dermatological Treatment</i> , 2016, 27, 99-102.	2.2	22
347	Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 716-721.	2.2	22
348	Follow-up survey of 308-nm laser treatment of psoriasis. <i>Lasers in Surgery and Medicine</i> , 2002, 31, 202-206.	2.1	21
349	The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 79-82.	1.2	21
350	Treatment of pityriasis versicolor in the United States. <i>Journal of Dermatological Treatment</i> , 2004, 15, 189-192.	2.2	21
351	Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. <i>Journal of Dermatological Treatment</i> , 2005, 16, 158-164.	2.2	21
352	Side effects of naltrexone observed in frequent tanners: Could frequent tanners have ultraviolet-induced high opioid levels?. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 916.	1.2	21
353	Cutaneous lupus erythematosus simulating squamous neoplasia: The clinicopathologic conundrum and histopathologic pitfalls. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 1013-1020.	1.2	21
354	An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. <i>JAMA Dermatology</i> , 2017, 153, 932.	4.1	21
355	Tolerability of Topical Treatments for Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2019, 9, 71-102.	3.0	21
356	Psoriasis causes as much disability as other major medical diseases. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 256-257.	1.2	21
357	The Challenge of Managing Atopic Dermatitis in the United States. <i>American Health and Drug Benefits</i> , 2019, 12, 83-93.	0.5	21
358	Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. <i>Journal of Drugs in Dermatology</i> , 2010, 9, 324-9.	0.8	21
359	JAK inhibitors in psoriasis: a promising new treatment modality. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 913-8.	0.8	21
360	A maintenance protocol for psoriasis plaques cleared by the 308-nm excimer laser. <i>Journal of Dermatological Treatment</i> , 2004, 15, 94-97.	2.2	20

#	ARTICLE	IF	CITATIONS
361	Validation and Reliability of 2 Specialty Care Satisfaction Scales. American Journal of Medical Quality, 2009, 24, 12-18.	0.5	20
362	Rheumatologists'™ recommendations on what to do in the dermatology office to evaluate and manage psoriasis patients'™ joint symptoms. Journal of Dermatological Treatment, 2009, 20, 350-353.	2.2	20
363	Treatment Sequencing After Failure of the First Biologic in Cost-Effectiveness Models of Psoriasis: A Systematic Review of Published Models and Clinical Practice Guidelines. Pharmacoeconomics, 2014, 32, 395-409.	3.3	20
364	Phototherapy in Scleroderma. Dermatology and Therapy, 2016, 6, 519-553.	3.0	20
365	Relative versus absolute risk of comorbidities in patients with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 531-537.	1.2	20
366	Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Review of Clinical Pharmacology, 2017, 10, 1049-1054.	3.1	20
367	A Review of the Use of Secukinumab for Psoriatic Arthritis. Rheumatology and Therapy, 2017, 4, 233-246.	2.3	20
368	Prescriptions for atopic dermatitis: oral corticosteroids remain commonplace. Journal of Dermatological Treatment, 2018, 29, 238-240.	2.2	20
369	Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. Journal of the American Academy of Dermatology, 2019, 80, 1650-1657.	1.2	20
370	Comorbidity of Tinea Pedis and Onychomycosis and Evaluation of Risk Factors in Latino Immigrant Poultry Processing and Other Manual Laborers. Southern Medical Journal, 2014, 107, 374-379.	0.7	20
371	Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. Journal of Drugs in Dermatology, 2015, 14, 777-84.	0.8	20
372	Betamethasone Valerate in Foam Vehicle is Effective with Both Daily and Twice a Day Dosing: A Single-Blind, Open-Label Study in the Treatment of Scalp Psoriasis. Journal of Cutaneous Medicine and Surgery, 2001, 5, 386-389.	1.2	19
373	Bioavailability of Clobetasol Propionate in Different Vehicles. Skin Pharmacology and Physiology, 2003, 16, 212-216.	2.5	19
374	Healthcare Utilization for Acute and Chronic Diseases of Young, School-age Children in the Rural and Non-rural Setting. Clinical Pediatrics, 2005, 44, 491-498.	0.8	19
375	Self report of skin problems among farmworkers in North Carolina. American Journal of Industrial Medicine, 2008, 51, 204-212.	2.1	19
376	The prevalence and possible causes of contact dermatitis in farmworkers. International Journal of Dermatology, 2009, 48, 1166-1170.	1.0	19
377	Review: timing of office visits can be a powerful tool to improve adherence in the treatment of dermatologic conditions. Journal of Dermatological Treatment, 2013, 24, 82-88.	2.2	19
378	Systemic Corticosteroids Are Frequently Prescribed for Psoriasis. Journal of Cutaneous Medicine and Surgery, 2014, 18, 195-199.	1.2	19

#	ARTICLE	IF	CITATIONS
379	A Review of the Use of Tanning Beds as a Dermatological Treatment. <i>Dermatology and Therapy</i> , 2015, 5, 37-51.	3.0	19
380	Review of patient registries in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 824-829.	1.2	19
381	Recognition of Sleep Apnea Is Increasing. Analysis of Trends in Two Large, Representative Databases of Outpatient Practice. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2027-2034.	3.2	19
382	Current status and future prospects for biologic treatments of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1273-1287.	3.0	19
383	Ivermectin 1% (CD5024) for the treatment of rosacea. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 511-516.	1.8	19
384	Adherence to Adalimumab in Patients with Moderate to Severe Psoriasis. <i>Dermatology Online Journal</i> , 2013, 19, .	0.5	19
385	Adherence to adalimumab in patients with moderate to severe psoriasis. <i>Dermatology Online Journal</i> , 2013, 19, 18182.	0.5	19
386	Psychosocial impact of psoriasis: a review for dermatology residents. <i>Cutis</i> , 2018, 102, 21-25.	0.3	19
387	Terbinafine is More Effective Than Itraconazole in Treating Toenail Onychomycosis: Results from a Meta-analysis of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 306-311.	1.2	18
388	Frequency of Seborrheic Keratosis Biopsies in the United States: A Benchmark of Skin Lesion Care Quality and Cost Effectiveness. <i>Dermatologic Surgery</i> , 2003, 29, 796-801.	0.8	18
389	No Smoking Gun: Findings From a National Survey of Office-Based Cosmetic Surgery Adverse Event Reporting. <i>Dermatologic Surgery</i> , 2003, 29, 1093-1099.	0.8	18
390	Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2003, 29, 700-711.	0.8	18
391	Dermatological Illnesses of Immigrant Poultry-Processing Workers in North Carolina. <i>Archives of Environmental and Occupational Health</i> , 2005, 60, 165-169.	1.4	18
392	Adherence to topical hydrocortisone 17-butyrate 0.1% in different vehicles in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 166-168.	1.2	18
393	Trends in home phototherapy adoption in the US: Monetary disincentives are only the tip of the iceberg. <i>Journal of Dermatological Treatment</i> , 2011, 22, 27-30.	2.2	18
394	Use of topical retinoids by dermatologists and non-dermatologists in the management of acne vulgaris. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1252-1254.	1.2	18
395	Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1209-1218.	3.1	18
396	Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families. <i>Dermatology and Therapy</i> , 2018, 8, 605-619.	3.0	18

#	ARTICLE	IF	CITATIONS
397	Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. <i>Children</i> , 2019, 6, 103.	1.5	18
398	Tildrakizumab: A Review of Phase II and III Clinical Trials. <i>Annals of Pharmacotherapy</i> , 2019, 53, 413-418.	1.9	18
399	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020, 10, 351-364.	3.0	18
400	Tolerability of and Adherence to Topical Treatments in Atopic Dermatitis: A Narrative Review. <i>Dermatology and Therapy</i> , 2021, 11, 415-431.	3.0	18
401	Critical factors determining the potency of topical corticosteroids. <i>Journal of Dermatological Treatment</i> , 2006, 17, 133-135.	2.2	17
402	Do utilization management controls for phototherapy increase the prescription of biologics?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 359-361.	2.2	17
403	Contact dermatitis in tobacco farmworkers. <i>Contact Dermatitis</i> , 2007, 57, 40-43.	1.4	17
404	The cost-effectiveness of rosacea treatments. <i>Journal of Dermatological Treatment</i> , 2009, 20, 72-75.	2.2	17
405	Sticker Charts: A Method for Improving Adherence to Treatment of Chronic Diseases in Children. <i>Pediatric Dermatology</i> , 2012, 29, 403-408.	0.9	17
406	Cosmetic Procedures Performed in the United States: A 16-Year Analysis. <i>Dermatologic Surgery</i> , 2013, 39, 1351-1359.	0.8	17
407	Quality of Life of Patients With Pyoderma Gangrenosum and Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 391-396.	1.2	17
408	Rosacea Triggers. <i>Dermatologic Clinics</i> , 2018, 36, 123-126.	1.7	17
409	Treatment Goals in Psoriasis: Which Outcomes Matter Most?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 505-511.	6.7	17
410	Topical methotrexate in dermatology: a review of the literature. <i>Journal of Dermatological Treatment</i> , 2022, 33, 512-517.	2.2	17
411	Phototherapy: a Review and Update of Treatment Options in Dermatology. <i>Current Dermatology Reports</i> , 2020, 9, 10-21.	2.1	17
412	A changed life: the life experiences of patients with psoriasis receiving biological treatment. <i>British Journal of Dermatology</i> , 2020, 183, 516-523.	1.5	17
413	Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. <i>Dermatologic Therapy</i> , 2021, 34, e14833.	1.7	17
414	Underuse of early follow-up visits: a missed opportunity to improve patients' adherence. <i>Journal of Drugs in Dermatology</i> , 2014, 13, 833-6.	0.8	17



#	ARTICLE	IF	CITATIONS
415	Social impact of the burden of psoriasis: effects on patients and practice. <i>Dermatology Online Journal</i> , 2014, 20, .	0.5	17
416	Physicians underutilize topical retinoids in the management of acne vulgaris: analysis of U.S. National Practice Data. <i>Journal of Dermatological Treatment</i> , 2003, 14, 172-176.	2.2	16
417	The Importance of Skin Disease as Assessed by "Willingness-To-Pay". <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 369-371.	1.2	16
418	A topical azithromycin preparation for the treatment of acne vulgaris and rosacea. <i>Journal of Dermatological Treatment</i> , 2004, 15, 295-302.	2.2	16
419	Increase in Procedures Performed at Dermatology Office Visits from 1995 to 2001. <i>Dermatologic Surgery</i> , 2005, 31, 160-162.	0.8	16
420	Adverse Event Reporting: Lessons Learned from 4 Years of Florida Office Data. <i>Dermatologic Surgery</i> , 2006, 31, 1079-1093.	0.8	16
421	Nonmelanoma Skin Cancer: Is the Incidence Really Increasing among Patients Younger Than 40? A Reexamination Using 25 years of U.S. Outpatient Data. <i>Dermatologic Surgery</i> , 2006, 32, 1473-1479.	0.8	16
422	How much of a topical agent should be prescribed for children of different sizes?. <i>Journal of Dermatological Treatment</i> , 2006, 17, 224-228.	2.2	16
423	Patient Satisfaction with Outpatient Medical Care in the United States. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e197-e202.	0.6	16
424	Maternal Adherence Factors in the Treatment of Pediatric Atopic Dermatitis. <i>JAMA Dermatology</i> , 2013, 149, 229.	4.1	16
425	Topical antibiotic monotherapy prescribing practices in acne vulgaris. <i>Journal of Dermatological Treatment</i> , 2014, 25, 97-99.	2.2	16
426	Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 617-622.	0.9	16
427	Adherence and resource use among psoriasis patients treated with biologics. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 609-617.	1.4	16
428	Clinical effectiveness of novel rosacea therapies. <i>Current Opinion in Pharmacology</i> , 2019, 46, 14-18.	3.5	16
429	Diet-Related Phototoxic Reactions in Psoriatic Patients Undergoing Phototherapy: Results from a Multicenter Prospective Study. <i>Nutrients</i> , 2021, 13, 2934.	4.1	16
430	Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 86-98.	1.9	16
431	The design of clinical trials in psoriasis: lessons for clinical practice. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 62-65.	1.2	15
432	Giving patients "perceived control" over psoriasis: advice for optimizing the physician-patient relationship. <i>Journal of Dermatological Treatment</i> , 2004, 15, 182-184.	2.2	15

#	ARTICLE	IF	CITATIONS
433	Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 27-31.	1.2	15
434	The association of dermatologist-diagnosed and self-reported skin diseases with skin-related quality of life in Latino migrant farmworkers. <i>International Journal of Dermatology</i> , 2008, 47, 236-241.	1.0	15
435	The association of skin conditions with housing conditions among North Carolina Latino migrant farm workers. <i>International Journal of Dermatology</i> , 2014, 53, 1091-1097.	1.0	15
436	Entrance and propagation pattern of high-frequency electrical currents in biological tissues as applied to fractional skin rejuvenation using penetrating electrodes. <i>Skin Research and Technology</i> , 2014, 20, 270-273.	1.6	15
437	Use of St. John's Wort in Potentially Dangerous Combinations. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, 578-579.	2.1	15
438	Dupilumab for atopic dermatitis. <i>Lancet, The</i> , 2017, 389, 2265-2266.	13.7	15
439	A Review of the Current Modalities for the Treatment of Papulopustular Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 135-150.	1.7	15
440	Validation of a Hidradenitis Suppurativa Self-Assessment Tool. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 388-390.	1.2	15
441	An increasing trend in the number of publications and research projects among dermatology residency applicants. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 214-216.	1.2	15
442	Development of an mHealth App for Patients With Psoriasis Undergoing Biological Treatment: Participatory Design Study. <i>JMIR Dermatology</i> , 2021, 4, e26673.	0.7	15
443	The evolving atopic dermatitis management landscape. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 517-526.	1.8	15
444	Women commonly seek care for rosacea: dermatologists frequently provide the care. <i>Cutis</i> , 2001, 68, 156-60.	0.3	15
445	Corrective cosmetics are effective for women with facial pigmentary disorders. <i>Cutis</i> , 2005, 75, 181-7.	0.3	15
446	Are ointments better than other vehicles for corticosteroid treatment of psoriasis?. <i>Journal of Drugs in Dermatology</i> , 2009, 8, 570-2.	0.8	15
447	The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 438-46.	0.8	15
448	Adherence to ustekinumab in psoriasis patients. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 1090-2.	0.8	15
449	Definitions of Measures of Effect Duration for Psoriasis Treatments. <i>Psoriasis Forum</i> , 2002, 8a, 1-5.	0.1	14
450	Using "number needed to treat" to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-1 $\alpha$ inhibitors for patients with severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 161, 605-616.	1.5	14

#	ARTICLE	IF	CITATIONS
451	Reappraising the phototoxicity of tretinoin: a report of four controlled clinical trials. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 146-152.	1.5	14
452	Treatment of Becker nevus with topical flutamide. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e147-e148.	1.2	14
453	Dermatologist-diagnosed skin diseases among immigrant Latino poultry processors and other manual workers in North Carolina, USA. <i>International Journal of Dermatology</i> , 2013, 52, 1342-1348.	1.0	14
454	Advances in treating psoriasis in the elderly with small molecule inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1965-1973.	1.8	14
455	Adherence to biologics in patients with psoriasis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 155-161.	3.0	14
456	Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis. <i>Children</i> , 2019, 6, 125.	1.5	14
457	Differences in healthcare barriers based on racial and/or ethnic background for patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2019, 32, 1-5.	2.2	14
458	Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 443-454.	1.8	14
459	Real-world US healthcare costs of psoriasis for biologic-naïve patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 45-54.	1.4	14
460	Improving psoriasis patients' adherence to topical drugs: a systematic review. <i>Journal of Dermatological Treatment</i> , 2020, 31, 776-785.	2.2	14
461	Patients preferences for different corticosteroid vehicles are highly variable. <i>Journal of Dermatological Treatment</i> , 2020, 31, 147-151.	2.2	14
462	Difference in vasoconstrictors: oxymetazoline vs. brimonidine. <i>Journal of Dermatological Treatment</i> , 2021, 32, 137-143.	2.2	14
463	Surge in US Outpatient Vitamin D Deficiency Diagnoses: National Ambulatory Medical Care Survey Analysis. <i>Southern Medical Journal</i> , 2014, 107, 214-217.	0.7	14
464	Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2018, 11, 47-52.	0.1	14
465	Conformation-specific precipitation of human $\lambda$ 2-macroglobulin by divalent zinc or calf thymus histone H3. <i>Archives of Biochemistry and Biophysics</i> , 1984, 233, 462-468.	3.0	13
466	Implications of a utility model for ultraviolet exposure behavior. <i>Journal of the American Academy of Dermatology</i> , 2001, 45, 718-722.	1.2	13
467	Surgical Treatment of Nonmelanoma Skin Cancer in the Medicare Population. <i>Dermatologic Surgery</i> , 2003, 29, 1167-1169.	0.8	13
468	Surgery for basal-cell carcinoma of the face. <i>Lancet</i> , The, 2004, 364, 1732-1733.	13.7	13

#	ARTICLE	IF	CITATIONS
469	Increase in Procedures Performed at Dermatology Office Visits from 1995 to 2001. <i>Dermatologic Surgery</i> , 2006, 31, 160-162.	0.8	13
470	Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. <i>Current Medical Research and Opinion</i> , 2008, 24, 3493-3501.	1.9	13
471	Home Narrowband UV-B Phototherapy in Combination With Low-Dose Acitretin in Patients With Moderate to Severe Psoriasis. <i>Archives of Dermatology</i> , 2008, 144, 1224-5.	1.4	13
472	Pilot Study of the Effect of Ultraviolet Light on Pain and Mood in Fibromyalgia Syndrome. <i>Journal of Alternative and Complementary Medicine</i> , 2009, 15, 15-23.	2.1	13
473	Dermatologic Medication Adherence. <i>Dermatologic Clinics</i> , 2009, 27, 113-120.	1.7	13
474	Podcasting in dermatology education. <i>Journal of Dermatological Treatment</i> , 2010, 21, 73-79.	2.2	13
475	Practice Trends in the Treatment of Actinic Keratosis in the United States: 0.5% Fluorouracil and Combination Cryotherapy plus Fluorouracil are Underused despite Evidence of Benefit. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 107-114.	1.2	13
476	Are corticosteroids effective for prevention of scar formation after second-degree skin burn?. <i>Journal of Dermatological Treatment</i> , 2014, 25, 360-362.	2.2	13
477	Measure of Atopic Dermatitis Disease Severity Using Actigraphy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 49-55.	1.2	13
478	Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized. <i>Dermatology and Therapy</i> , 2015, 5, 91-105.	3.0	13
479	Ethical considerations in adherence research. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2429-2435.	1.8	13
480	Tazarotene foam, 0.1%, for the treatment of acne. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 99-103.	2.4	13
481	Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. <i>Pharmacoeconomics</i> , 2017, 35, 177-190.	3.3	13
482	Medical Management of Facial Redness in Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 151-159.	1.7	13
483	Coping Mechanisms and Resources for Patients Suffering from Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 171-174.	1.7	13
484	Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1489-1497.	2.0	13
485	Home UV Phototherapy. <i>Dermatologic Clinics</i> , 2020, 38, 109-126.	1.7	13
486	International collaboration and rapid harmonization across dermatologic COVID-19 registries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e261-e266.	1.2	13

#	ARTICLE	IF	CITATIONS
487	Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. <i>BioDrugs</i> , 2021, 35, 735-748.	4.6	13
488	Effects of systematic asymmetric discounting on physician-patient interactions: a theoretical framework to explain poor compliance with lifestyle counseling. <i>BMC Medical Informatics and Decision Making</i> , 2002, 2, 8.	3.0	12
489	Class I topical corticosteroid use by psoriasis patients in an academic practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 235-238.	2.2	12
490	Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice. <i>Journal of Dermatological Treatment</i> , 2004, 15, 208-213.	2.2	12
491	Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. <i>Current Therapeutic Research</i> , 2005, 66, 154-171.	1.2	12
492	Adapting electronic adherence monitors to standard packages of topical medications. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 886-887.	1.2	12
493	Skin-Related Quality of Life among Migrant Farmworkers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2008, 12, 1-7.	1.2	12
494	Patients' educational needs about topical treatments for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e163-e168.	1.2	12
495	Skin Manifestations of Outpatient Adverse Drug Events in the United States: A National Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 269-275.	1.2	12
496	Noncosmetic Skin-Related Procedures Performed in the United States: An Analysis of National Ambulatory Medical Care Survey Data from 1995 to 2010. <i>Dermatologic Surgery</i> , 2013, 39, 1912-1921.	0.8	12
497	Improving medication adherence through technology: analyzing the managing meds video challenge. <i>Skin Research and Technology</i> , 2014, 20, 62-66.	1.6	12
498	Current Drug Therapies for Rosacea: A Chronic Vascular and Inflammatory Skin Disease. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 623-629.	2.2	12
499	Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 200-205.	2.2	12
500	An update on the topical and oral therapy options for treating pediatric atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 621-629.	1.8	12
501	Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population. <i>Journal of Dermatological Treatment</i> , 2021, 32, 595-602.	2.2	12
502	Dermatology COVID-19 Registries. <i>Dermatologic Clinics</i> , 2021, 39, 575-585.	1.7	12
503	Improvement in treatment adherence with a 3-day course of fluocinonide cream 0.1% for atopic dermatitis. <i>Cutis</i> , 2010, 86, 208-13.	0.3	12
504	The Importance of Skin Disease as Assessed by "Willingness-To-Pay". <i>Journal of Cutaneous Medicine and Surgery</i> , 2003, 7, 369-371.	1.2	11

#	ARTICLE	IF	CITATIONS
505	Racial differences in the treatment of pigmentation disorders in outpatient settings: analysis of US national practice data. <i>Journal of Dermatological Treatment</i> , 2004, 15, 227-230.	2.2	11
506	UV Light Abuse as a Substance-Related Disorder. <i>Archives of Dermatology</i> , 2008, 144, 1047-8.	1.4	11
507	Drug samples in dermatology: Special considerations and recommendations for the future. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 1053-1061.	1.2	11
508	Patient satisfaction with obstetricians and gynecologists compared with other specialties: analysis of US self-reported survey data. <i>Patient Related Outcome Measures</i> , 2011, 2, 21.	1.2	11
509	Topical Antibiotic Trends from 1993 to 2007: Use of Topical Antibiotics for Non-Evidence-Based Indications. <i>Dermatologic Surgery</i> , 2011, 37, 1427-1433.	0.8	11
510	Apremilast as a treatment for psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1761-1770.	1.8	11
511	Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. <i>Journal of Dermatological Treatment</i> , 2013, 24, 101-106.	2.2	11
512	Focusing and depth of field in photography: application in dermatology practice. <i>Skin Research and Technology</i> , 2013, 19, n/a-n/a.	1.6	11
513	Current and future evidence-based acne treatment: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 173-192.	1.8	11
514	Review of maintenance of response to psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2016, 27, 293-297.	2.2	11
515	The safety of treatments used in pyoderma gangrenosum. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 55-61.	2.4	11
516	Tracking the price of existing biologics when drugs enter the market. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 375-377.	1.4	11
517	Sarecycline Review. <i>Annals of Pharmacotherapy</i> , 2020, 54, 164-170.	1.9	11
518	Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Annals of Pharmacotherapy</i> , 2020, 54, 380-387.	1.9	11
519	Steroid phobia isn't reduced by improving patients' knowledge of topical corticosteroids. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e403-e404.	1.2	11
520	Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. <i>Dermatology and Therapy</i> , 2021, 11, 1373-1384.	3.0	11
521	Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2270-2277.	2.2	11
522	Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 221-231.	3.0	11

#	ARTICLE	IF	CITATIONS
523	Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. <i>Cutis</i> , 2009, 84, 25-32.	0.3	11
524	Analysis of factors associated with prescription of a potentially inappropriate combination dermatological medication among US outpatient physicians. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 133-138.	1.9	10
525	Measurement of health-related quality of life (HRQOL) associated with skin disease. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 3-4.	1.2	10
526	Analysis of NAMCS data for multiple sclerosis, 1998â€“2004. <i>BMC Medicine</i> , 2007, 5, 6.	5.5	10
527	â€Coral reefâ€™ psoriasis: A marker of resistance to topical treatment. <i>Journal of Dermatological Treatment</i> , 2008, 19, 257-258.	2.2	10
528	Continued use of home narrowband ultraviolet B light phototherapy for psoriasis after completion of a clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 877-879.	1.2	10
529	Health behaviour models: a framework for studying adherence in children with atopic dermatitis. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 228-232.	1.3	10
530	Efficacy and Safety of Calcipotriene 0.005% Foam for the Treatment of Plaque-Type Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 261-271.	6.7	10
531	Interleukin 17 deficiency and implications in cutaneous and systemic diseases. <i>Journal of Dermatology &amp; Dermatologic Surgery</i> , 2015, 19, 73-79.	0.2	10
532	Dupilumab for the treatment of atopic dermatitis: A clinical trial review. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1657-1660.	3.1	10
533	Chemical pharmacotherapy options for managing adult acne. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 263-273.	1.8	10
534	Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2017, Volume 10, 385-391.	1.8	10
535	Review of future insights of Dragon's Blood in dermatology. <i>Dermatologic Therapy</i> , 2019, 32, e12786.	1.7	10
536	Treatment of keratosis pilaris and its variants: a systematic review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1231-1242.	2.2	10
537	Pharmacological management of atopic dermatitis in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 761-771.	1.8	10
538	A review of secukinumab in psoriasis treatment. <i>Immunotherapy</i> , 2021, 13, 201-216.	2.0	10
539	Abametapir for the Treatment of Head Lice: A Drug Review. <i>Annals of Pharmacotherapy</i> , 2022, 56, 352-357.	1.9	10
540	1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses. <i>Annals of Pharmacotherapy</i> , 2022, 56, 494-500.	1.9	10

#	ARTICLE	IF	CITATIONS
541	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2503-2509.	2.2	10
542	Advances in Psoriasis. <i>Southern Medical Journal</i> , 2017, 110, 65-75.	0.7	10
543	Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 2016, 4, 141-157.	1.2	10
544	Long-term improvement of psoriasis patients' adherence to topical drugs: testing a patient-supporting intervention delivered by healthcare professionals. <i>Trials</i> , 2021, 22, 742.	1.6	10
545	Psoriasis treatment. <i>Current Problems in Dermatology</i> , 1998, 10, 1-40.	0.0	9
546	The Frequent Use of Oral Retinoids in Combination with Other Treatments for Psoriasis: A Retrospective Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 411-414.	1.2	9
547	Prescription refills and healthcare costs associated with topical metronidazole in Medicaid enrolled patients with rosacea. <i>Journal of Dermatological Treatment</i> , 2008, 19, 267-273.	2.2	9
548	Adherence, the Fourth Dimension in the Geometry of Dermatological Treatment. <i>Archives of Dermatology</i> , 2009, 145, 1319-21.	1.4	9
549	Prescribing patterns for topical retinoids: Analyses of 15 years of data from the National Ambulatory Medical Care Survey. <i>Journal of Dermatological Treatment</i> , 2010, 21, 193-200.	2.2	9
550	Prior authorization for topical psoriasis treatments: Is it cost-beneficial for managed care?. <i>Journal of Dermatological Treatment</i> , 2010, 21, 178-184.	2.2	9
551	Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 654-665.	0.9	9
552	Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 789-797.	3.1	9
553	Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 583-589.	0.9	9
554	Insights into future therapeutics for atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 265-278.	1.8	9
555	Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 380-387.	1.9	9
556	A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 523-536.	2.4	9
557	Even mild hidradenitis suppurativa impairs quality of life. <i>British Journal of Dermatology</i> , 2019, 181, 838-839.	1.5	9
558	The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 446-453.	2.2	9



#	ARTICLE	IF	CITATIONS
559	An update on the impact of depression on the treatment of psoriasis. Expert Opinion on Pharmacotherapy, 2021, 22, 695-703.	1.8	9
560	Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. Journal of Dermatological Treatment, 2021, 32, 203-211.	2.2	9
561	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clinics in Dermatology, 2021, 39, 467-478.	1.6	9
562	Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 143-150.	0.7	9
563	Patient and caregiver preferences on treatment attributes for atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 2225-2233.	2.2	9
564	Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2021, 157, 1306.	4.1	9
565	Comparing available JAK inhibitors for treating patients with psoriasis. Expert Review of Clinical Immunology, 2022, 18, 281-294.	3.0	9
566	Is prior authorization of topical tretinoin for acne cost effective?. American Journal of Managed Care, 1999, 5, 457-63.	1.1	9
567	Correspondence. Journal of Dermatological Treatment, 2004, 15, 252-252.	2.2	8
568	Indoor tanning relieves pain. Photodermatology Photoimmunology and Photomedicine, 2005, 21, 278-278.	1.5	8
569	Death from psoriasis: Representative US data. Journal of Dermatological Treatment, 2006, 17, 302-303.	2.2	8
570	Common Skin Disorders Seen in the Migrant Farmworker Health Care Clinic Setting. Journal of Agromedicine, 2008, 12, 71-79.	1.5	8
571	The pharmacoeconomics of acne treatment: Where are we heading?. Journal of Dermatological Treatment, 2008, 19, 27-37.	2.2	8
572	Microscopically differentiating dermatophytes from sock fibers. Journal of the American Academy of Dermatology, 2009, 61, 1024-1027.	1.2	8
573	Estimating the time required for a complete skin examination. Journal of the American Academy of Dermatology, 2010, 62, 886-888.	1.2	8
574	Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. Journal of Dermatological Treatment, 2012, 23, 196-202.	2.2	8
575	A disease of the present: Scurvy in "well-nourished" patients. Journal of the American Academy of Dermatology, 2013, 69, e246-e247.	1.2	8
576	Self-reported skin symptoms and skin-related quality of life among Latino immigrant poultry processing and other manual workers. American Journal of Industrial Medicine, 2014, 57, 605-614.	2.1	8

#	ARTICLE	IF	CITATIONS
577	What's new in the topical treatment of allergic skin diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 436-450.	2.3	8
578	Topical antimicrobial acne treatment tolerability: A meaningful factor in treatment adherence?. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 581-582.e2.	1.2	8
579	Training for prescribing in office and home phototherapy. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2015, 31, 325-332.	1.5	8
580	Internet-based adherence interventions for treatment of chronic disorders in adolescents. <i>Adolescent Health, Medicine and Therapeutics</i> , 2015, 6, 91.	0.9	8
581	The most common dermatology diagnoses in the emergency department. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1261-1262.	1.2	8
582	The cost of applying to dermatology residency. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 775-776.	1.2	8
583	Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. <i>American Journal of the Medical Sciences</i> , 2018, 355, 411-417.	1.1	8
584	Effectiveness of the Tacrolimus Swish-and-Spit Treatment Regimen in Patients With Geographic Tongue. <i>JAMA Dermatology</i> , 2018, 154, 1481.	4.1	8
585	&lt;p&gt;Accountability in patient adherence&lt;/p&gt;. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1511-1517.	1.8	8
586	Regardless of how risks are framed, patients seem hesitant to use topical steroids for atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 181, 842-844.	1.5	8
587	Abnormal liver function tests in acne patients receiving isotretinoin. <i>Journal of Dermatological Treatment</i> , 2021, 32, 469-472.	2.2	8
588	Improving management of psoriasis patients receiving biological treatment: A qualitative approach. <i>Nursing Open</i> , 2021, 8, 1283-1291.	2.4	8
589	Self-Treatment with Bleach by a Latino Farmworker. <i>Dermatitis</i> , 2008, 19, 102-104.	1.6	8
590	New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature. <i>Dermatologic Therapy</i> , 2021, 34, e15151.	1.7	8
591	Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. <i>Cutis</i> , 2007, 80, 20-8.	0.3	8
592	A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 300-6.	0.8	8
593	Dermatologists and Allergists Have Far More Experience and Use More Complex Treatment Regimens in the Treatment of Atopic Dermatitis Than Other Physicians. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 211-216.	1.2	7
594	The Frequent Use of Oral Retinoids in Combination with other Treatments for Psoriasis: A Retrospective Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 411-414.	1.2	7

#	ARTICLE	IF	CITATIONS
595	The utility of a data-logging device for measuring adherence to home phototherapy. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2006, 22, 270-272.	1.5	7
596	A role for denial in poor adherence to psoriasis treatment. <i>Journal of Dermatological Treatment</i> , 2007, 18, 324-325.	2.2	7
597	Does cost-effectiveness play a role in clinical trials?. <i>Dermatologic Therapy</i> , 2007, 20, 110-119.	1.7	7
598	US dermatopathology fellows career survey: 2004-2005. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 487-489.	1.3	7
599	Monitoring for medication errors in outpatient settings. <i>Journal of Dermatological Treatment</i> , 2009, 20, 229-232.	2.2	7
600	Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. <i>Journal of Dermatological Treatment</i> , 2010, 21, 276-281.	2.2	7
601	Isotretinoin and oral contraceptive use in female acne patients varies by physician specialty: analysis of data from the National Ambulatory Medical Care Survey. <i>Journal of Dermatological Treatment</i> , 2012, 23, 272-277.	2.2	7
602	Measuring patient satisfaction changes patient satisfaction. <i>Journal of Dermatological Treatment</i> , 2012, 23, 81-82.	2.2	7
603	A Conservative Method to Gutter Splint Ingrown Toenails. <i>JAMA Dermatology</i> , 2014, 150, 1359.	4.1	7
604	Assessing Medication Adherence Using Indirect Self-report. <i>JAMA Dermatology</i> , 2014, 150, 813.	4.1	7
605	Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 361-366.	1.2	7
606	Physicians Report Sleep Apnea Infrequently in Older and Older Vulnerable Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2023-2028.	2.6	7
607	Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. <i>Journal of Medical Economics</i> , 2017, 20, 1000-1006.	2.1	7
608	Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 70-85.	4.7	7
609	Treatment Changes in Patients With Moderate to Severe Psoriasis: A Retrospective Chart Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 25-30.	1.2	7
610	Complementary and Integrative Therapies for Childhood Atopic Dermatitis. <i>Children</i> , 2019, 6, 121.	1.5	7
611	Treatment patterns and costs among biologic-naïve patients initiating apremilast or biologics for psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 699-709.	1.4	7
612	Asymptomatic Crohn's disease identified in a patient being treated with secukinumab: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1989358.	0.3	7

#	ARTICLE	IF	CITATIONS
613	Hidradenitis suppurativa has an enormous impact on patients' lives. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 236-238.	1.2	7
614	Assessing the Effect of Clinical Trial Evidence and Anecdote on Caregivers'™ Willingness to Use Corticosteroids: A Randomized Controlled Trial. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 17-22.	1.2	7
615	Transcutaneous electrical nerve stimulation (TENS): a review of applications in dermatology. <i>Journal of Dermatological Treatment</i> , 2020, 31, 846-849.	2.2	7
616	Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1208-1212.	2.2	7
617	Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 693-700.	2.2	7
618	Placebo tailoring improves patient satisfaction of treatment plans in atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 944-946.	1.2	7
619	Dapsone as corticosteroid-sparing therapy for Sweet syndrome. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 677-679.	1.2	7
620	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1670-1675.	2.2	7
621	Controversial cardiovascular and hematologic comorbidities in atopic dermatitis. <i>Archives of Dermatological Research</i> , 2022, 314, 317-324.	1.9	7
622	Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS). <i>Dermatology and Therapy</i> , 2021, 11, 2077-2088.	3.0	7
623	Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population. <i>Dermatology</i> , 2022, 238, 438-447.	2.1	7
624	Practical Strategies to Improve Patient Adherence to Treatment Regimens. <i>Southern Medical Journal</i> , 2015, 108, 325-31.	0.7	7
625	Characterization of $\hat{I}\pm 2$ -macroglobulin receptor low density lipoprotein receptor-related protein ( $\hat{I}\pm 2$ MR/LRP) in White Carneau pigeon peritoneal macrophages: its role in lipoprotein metabolism. <i>Lipids and Lipid Metabolism</i> , 1997, 1344, 171-188.	2.6	6
626	Patients seen in a dermatology clinic have unmet preventive health care needs. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 706-709.	1.2	6
627	Patients with solar keratosis, particularly of the trunk or lower extremities, are at high risk for skin cancer development. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 717-718.	1.3	6
628	Where has Goeckerman treatment gone?. <i>Journal of Dermatological Treatment</i> , 2005, 16, 73-74.	2.2	6
629	Does the teratogenicity of isotretinoin outweigh its benefits?. <i>Journal of Dermatological Treatment</i> , 2005, 16, 190-192.	2.2	6
630	The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2005, 16, 324-326.	2.2	6

#	ARTICLE	IF	CITATIONS
631	Resident Education: Effect of the Sixth National Psoriasis Foundation Chief Residents' Meeting. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 16-20.	1.2	6
632	Methotrexate: Understanding the risk in psoriasis patients. <i>Journal of Dermatological Treatment</i> , 2009, 20, 311-313.	2.2	6
633	Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 791-793.	1.2	6
634	Efficacy of low-dose acitretin in the treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2012, 23, 400-403.	2.2	6
635	Patients' Satisfaction With Dermatology Residents. <i>Southern Medical Journal</i> , 2012, 105, 520-523.	0.7	6
636	Feasibility of actigraphy wristband monitoring of atopic dermatitis in children. <i>Skin Research and Technology</i> , 2014, 20, 510-514.	1.6	6
637	Comparing Demographic Characteristics and Adverse Event Rates at Two Dermatologic Surgery Practices. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 337-340.	1.2	6
638	Factors associated with topical retinoid prescriptions for acne. <i>Journal of Dermatological Treatment</i> , 2014, 25, 110-114.	2.2	6
639	The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 877-884.	1.4	6
640	Risk versus benefit or risk versus risk: Risk aversion in the medical decision making process. <i>Journal of Dermatological Treatment</i> , 2017, 28, 1-2.	2.2	6
641	Comorbidities in patients with psoriasis: The role of the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 191-192.	1.2	6
642	Depression in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 181, 1087-1088.	1.5	6
643	The Decoy Effect. <i>Journal of Dermatological Treatment</i> , 2019, 30, 1-1.	2.2	6
644	Assessment of Provider Utilization Through Skin Biopsy Rates. <i>Dermatologic Surgery</i> , 2019, 45, 1035-1041.	0.8	6
645	Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. <i>Journal of Dermatological Treatment</i> , 2019, 30, 519-521.	2.2	6
646	Current and emerging biologics for the treatment of pediatric atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1435-1445.	3.1	6
647	Methotrexate for the treatment of recalcitrant genital and extragenital lichen sclerosus: A retrospective series. <i>Dermatologic Therapy</i> , 2020, 33, e13473.	1.7	6
648	Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1773-1775.	1.2	6

#	ARTICLE	IF	CITATIONS
649	SECURE-Psoriasis: a de-identified registry of psoriasis patients diagnosed with COVID-19. <i>Journal of Dermatological Treatment</i> , 2020, 31, 327-327.	2.2	6
650	Bromhidrosis Treatment Modalities: A Literature Review. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	6
651	Oral dapsone for the treatment of generalized granuloma annulare: A retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 911-914.	1.2	6
652	Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review. <i>International Journal of Dermatology</i> , 2021, 60, e486-e492.	1.0	6
653	Clinical Characteristics and HealthCare Resource Utilization in Patients With Generalized Pustular Psoriasis: Real-World Evidence From a Large Claims-Based Dataset. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 151-158.	0.7	6
654	Methotrexate for generalized granuloma annulare: A 60% response rate in a retrospective case series of 15 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 201-203.	1.2	6
655	Bioterrorism Preparedness in the Dermatology Community. <i>Archives of Dermatology</i> , 2003, 139, 1657-8.	1.4	6
656	Illiteracy and the readability of patient education materials. A look at Health Watch. <i>North Carolina Medical Journal</i> , 1994, 55, 290-2.	0.2	6
657	Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1017-20.	1.2	6
658	Improving adherence to topical treatment. <i>Cutis</i> , 2009, 83, 215-7.	0.3	6
659	Screening for depression in rosacea patients. <i>Cutis</i> , 2018, 102, 36-38.	0.3	6
660	Incidence rates of comorbidities among patients with psoriasis in the United States. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	6
661	The Treatment of Primary Focal Hyperhidrosis. <i>Skin Therapy Letter</i> , 2019, 24, 1-7.	0.3	6
662	Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the United States. <i>Southern Medical Journal</i> , 2014, 107, 292-3.	0.7	6
663	Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 1037-1043.	1.8	6
664	Organic affective disorder in a patient with congenital adrenal hyperplasia. <i>Biological Psychiatry</i> , 1987, 22, 767-770.	1.3	5
665	PSORIASIS. <i>Medical Clinics of North America</i> , 1998, 82, 1135-1144.	2.5	5
666	Per-Gram Cost of Medication is by Itself a Poor Indicator for Comparing Costs of Different Psoriasis Treatments: A Retrospective Cohort Study of the Cost of Psoriasis Treatment with Topical Corticosteroids versus Topical Calcipotriene. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 121-125.	1.2	5

#	ARTICLE	IF	CITATIONS
667	Equating Topical Treatment of Severe Psoriasis to Keeping Money in a Mattress. <i>Journal of Dermatological Treatment</i> , 2009, 20, 1-2.	2.2	5
668	Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. <i>Journal of Dermatological Treatment</i> , 2009, 20, 238-240.	2.2	5
669	Literature is lacking in discussion of non-adherence in dermatology. <i>Journal of Dermatological Treatment</i> , 2010, 21, 109-110.	2.2	5
670	Psoriasis and its treatment with adalimumab. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 133-152.	3.1	5
671	Physician performance measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e29-e35.	1.2	5
672	Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1105-1112.	3.1	5
673	Can light-field photography ease focusing on the scalp and oral cavity?. <i>Skin Research and Technology</i> , 2013, 19, 288-290.	1.6	5
674	Online Reviews of Physicians. <i>JAMA Dermatology</i> , 2016, 152, 143.	4.1	5
675	Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States. <i>Journal of Dermatological Treatment</i> , 2017, 28, 119-128.	2.2	5
676	Nasal Valve Reconstruction Using a Titanium Implant: An Outcomes Study. <i>Craniofacial Trauma &amp; Reconstruction</i> , 2017, 10, 175-182.	1.3	5
677	The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 111-115.	2.2	5
678	Biologics are too complicated to duplicate: should we be worried about biosimilars?. <i>British Journal of Dermatology</i> , 2018, 179, 557-558.	1.5	5
679	Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States. <i>Dermatology and Therapy</i> , 2018, 8, 441-453.	3.0	5
680	The role of veterinarians in assisting clients identify and care for emotional support animals. <i>Journal of the American Veterinary Medical Association</i> , 2019, 254, 199-202.	0.5	5
681	Rosacea: Relative risk versus absolute risk of malignant comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 623-624.	1.2	5
682	Evaluating crisaborole as a treatment option for atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1057-1063.	1.8	5
683	Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. <i>Journal of Medical Economics</i> , 2019, 22, 53-62.	2.1	5
684	Utility of boron in dermatology. <i>Journal of Dermatological Treatment</i> , 2020, 31, 2-12.	2.2	5

#	ARTICLE	IF	CITATIONS
685	Overcoming poor adherence is a major hurdle to managing atopic dermatitis. <i>British Journal of Dermatology</i> , 2020, 182, 836-837.	1.5	5
686	Treatment practices for psoriasis and how they are changing. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 579-581.	1.2	5
687	Lifelong Impact of Severe Atopic Dermatitis on Quality of Life: A Case Report. <i>Dermatology and Therapy</i> , 2021, 11, 1065-1070.	3.0	5
688	Patient assessment of 5-fluorouracil and imiquimod for the treatment of actinic keratoses: a retrospective study of real-world effectiveness. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2075-2078.	2.2	5
689	An overview of adapalene and benzoyl peroxide once-daily topical gel as a therapeutic option for acne. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1661-1667.	1.8	5
690	Mycophenolate mofetil versus methotrexate for vulvar lichen planus: A 10-year retrospective cohort study demonstrates comparable efficacy and tolerability. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	5
691	Tobacco smoking contributes little to facial wrinkling. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 12, 133-139.	2.4	5
692	Hidradenitis and smoking. <i>British Journal of Dermatology</i> , 2018, 178, 810-811.	1.5	5
693	Cutaneous cryosurgery in the United States. <i>Journal of Dermatological Treatment</i> , 2016, 27, 91-4.	2.2	5
694	Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 756-762.	0.8	5
695	Dermatologists' knowledge of and preferences regarding topical steroids. <i>Journal of Drugs in Dermatology</i> , 2013, 12, 786-9.	0.8	5
696	Why Do Patients in the United States Seek Care from Dermatologists?. <i>Dermatology and Therapy</i> , 2022, 12, 1065-1072.	3.0	5
697	Review of Ruxolitinib in the Treatment of Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 207-216.	1.9	5
698	The biology and clinical application of systemic glucocorticoids. <i>Current Problems in Dermatology</i> , 1992, 4, 211-235.	0.0	4
699	1999 Special Olympics World Summer Games: Dermatologic health screening results. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 700-703.	1.2	4
700	Dermatologists and Allergists Have Far More Experience and Use More Complex Treatment Regimens in the Treatment of Atopic Dermatitis Than other Physicians. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 211-216.	1.2	4
701	Visual discrimination testing of ultraviolet transmitting and ultraviolet blocking acrylic thermoplastics. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 228-231.	1.5	4
702	Coding Multiple Diagnoses for Patient Visits at Which Procedures Were Performed: No Evidence for Abuse by Physicians. <i>Dermatologic Surgery</i> , 2003, 29, 150-154.	0.8	4



#	ARTICLE	IF	CITATIONS
703	The rise of the generic drug market and its implications for dermatology. <i>Journal of Dermatological Treatment</i> , 2005, 16, 295-298.	2.2	4
704	Cutaneous Larva Migrans in a Migrant Latino Farmworker. <i>Journal of Agromedicine</i> , 2007, 12, 45-48.	1.5	4
705	Quality of Dermatologic Care Delivered by Physician Assistants: An Analysis of Prescribing Behavior for the Combination Antifungal Agent Clotrimazole-Betamethasone. <i>Archives of Dermatology</i> , 2007, 143, 1591-2.	1.4	4
706	Systematic selection bias: A cause of dramatic errors in the inference of treatment effectiveness. <i>Journal of Dermatological Treatment</i> , 2008, 19, 68-71.	2.2	4
707	Bilateral chondrodermatitis nodularis chronica helices on the antihelix in an elderly woman. <i>International Journal of Dermatology</i> , 2010, 49, 472-474.	1.0	4
708	The clinical triage assistant: A new member of the dermatology health care team. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 1103-1105.	1.2	4
709	Insight into psoriasis management: Commercial perspectives for the U.S. psoriasis market. <i>Journal of Dermatological Treatment</i> , 2011, 22, 18-26.	2.2	4
710	Considerable variation among American dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. <i>International Journal of Dermatology</i> , 2014, 53, 385-389.	1.0	4
711	Patterns of ambulatory care usage and leading treatments for rosacea. <i>Journal of Dermatological Treatment</i> , 2014, 25, 275-277.	2.2	4
712	In-office compounding of lidocaine-epinephrine: An option for anesthesia preparation before skin biopsy. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 159-160.	1.2	4
713	Risankizumab for psoriasis. <i>Lancet</i> , 2018, 392, 616-617.	13.7	4
714	Caregiver willingness to treat atopic dermatitis is not much improved by anchoring. <i>Journal of Dermatological Treatment</i> , 2019, 30, 471-474.	2.2	4
715	Secukinumab rapidly improves EQ-5D health status in patients with psoriasis: Pooled analysis from four phase 3 trials. <i>Journal of Dermatological Treatment</i> , 2021, 32, 709-715.	2.2	4
716	College aspirations, gender sexuality alliances, and teacher support among diverse LGBTQ youth. <i>Educational Review</i> , 2022, 74, 281-297.	3.7	4
717	An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1027-1033.	1.8	4
718	Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. <i>Annals of Pharmacotherapy</i> , 2020, 54, 872-878.	1.9	4
719	Is topical treatment effective for psoriasis in patients who failed topical treatment?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 41-44.	2.2	4
720	Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1511-1520.	2.2	4

#	ARTICLE	IF	CITATIONS
721	How the National Ambulatory Medical Care Survey has been used to identify health disparities in the care of patients in the United States. <i>Journal of the National Medical Association</i> , 2021, 113, 504-514.	0.8	4
722	Psoriasis Severity and Cardiometabolic Risk Factors in a Representative US National Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 719-730.	6.7	4
723	Hydroxychloroquine for generalized granuloma annulare: 35% response rate in a retrospective case series of 26 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 144-147.	1.2	4
724	Virtual reality memory palace: An innovative dermatology education modality. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	4
725	Association between menopausal hormone therapy and incidence of psoriasis: a secondary analysis from the Women's Health Initiative randomized clinical trials. <i>British Journal of Dermatology</i> , 2021, 185, 669-671.	1.5	4
726	Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 669-672.	2.2	4
727	Severe and acute complications of biologics in psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 586-596.	0.2	4
728	How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?. <i>Expert Review of Clinical Immunology</i> , 2022, , 1-3.	3.0	4
729	Digital videography assessment of patients' experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. <i>Journal of Drugs in Dermatology</i> , 2012, 11, 919-25.	0.8	4
730	Evaluation of Methotrexate in the Management of Sweet Syndrome. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 532-533.	1.2	4
731	Cigarette smokers engage in more high risk ultraviolet light behavior and have different ultraviolet light attitudes and beliefs. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1996, 7, 193-195.	2.4	3
732	Management and costs of severe psoriasis: the role of new biologics. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 573-579.	1.4	3
733	Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 140-141.	1.2	3
734	An educational brochure helps improve patients' understanding of residents' role and level of training. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 165-167.	1.2	3
735	A Randomized, Double-Blind Clinical Trial of a Probiotic Nutritional Intervention in the Treatment of Mild to Moderate Non-Scalp Psoriasis. <i>Psoriasis Forum</i> , 2007, 13a, 12-15.	0.1	3
736	Update on infliximab: an intravenous biologic therapy for psoriasis. <i>Expert Review of Dermatology</i> , 2007, 2, 707-713.	0.3	3
737	Context and contrast. <i>Journal of Dermatological Treatment</i> , 2008, 19, 197-198.	2.2	3
738	Detecting Adverse Events in Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2010, 36, 8-14.	0.8	3

#	ARTICLE	IF	CITATIONS
739	A Medicare cost comparison of minor cutaneous procedures by surgical setting. <i>Journal of Dermatological Treatment</i> , 2010, 21, 101-106.	2.2	3
740	We Must Think Outside the Box to Understand Nonadherence. <i>Pediatric Dermatology</i> , 2011, 28, 353-353.	0.9	3
741	The compliance pyramid. <i>Journal of Dermatological Treatment</i> , 2011, 22, 185-186.	2.2	3
742	Who Will Take Care of Us? Exploring Differences in Respondents' Satisfaction with Primary Care vs Specialty Care Physicians. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e3-e10.	0.6	3
743	Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. <i>Journal of Medical Economics</i> , 2013, 16, 1405-1413.	2.1	3
744	Nonmelanoma skin cancer treatment training varies across different medical specialists. <i>Journal of Dermatological Treatment</i> , 2013, 24, 215-220.	2.2	3
745	Tangential Shave Removal of Basal Cell Carcinoma. <i>Dermatologic Surgery</i> , 2013, 39, 1945-1946.	0.8	3
746	Recruiting Underserved Mothers to Medical Research: Findings from North Carolina. <i>Journal of Health Care for the Poor and Underserved</i> , 2013, 24, 1801-1815.	0.8	3
747	Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2013, 7, 19.	1.8	3
748	The Patient Protection and Affordable Care Act's rationing of health care: Implications for dermatology. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 998-999.	1.2	3
749	Common Use of Prescription Off-label Acne Therapy in Children Younger Than 12 Years Old. <i>Pediatric Dermatology</i> , 2014, 31, 551-555.	0.9	3
750	Are wash outs needed in clinical trials of topical agents?. <i>Journal of Dermatological Treatment</i> , 2014, 25, 1-1.	2.2	3
751	Phototherapy trends in dermatology. <i>Journal of Dermatological Treatment</i> , 2014, 25, 487-488.	2.2	3
752	Treatment of Molluscum Contagiosum with Imiquimod in the United States: A Retrospective Cross-sectional Study. <i>Pediatric Dermatology</i> , 2016, 33, 227-228.	0.9	3
753	Erythrodermic psoriasis and severe hypotension requiring intensive care unit hospitalization: Poor treatment outcome as a result of poor adherence. <i>Journal of Dermatological Treatment</i> , 2016, 27, 134-135.	2.2	3
754	A Review and Update of Phototherapy Treatment Options for Psoriasis. <i>Current Dermatology Reports</i> , 2018, 7, 43-51.	2.1	3
755	The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. <i>Journal of Medical Economics</i> , 2018, 21, 537-541.	2.1	3
756	Validity and Reliability of a Rosacea Self-Assessment Tool. <i>Dermatologic Clinics</i> , 2018, 36, 93-96.	1.7	3

#	ARTICLE	IF	CITATIONS
757	Measurement of Disease Severity in a Population of Rosacea Patients. <i>Dermatologic Clinics</i> , 2018, 36, 97-102.	1.7	3
758	Most common dermatology diagnoses to the emergency department in the paediatric population. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e144-e146.	2.4	3
759	Applying behavioural economics to psoriasis treatment: interventions to improve patient adherence to biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e65-e66.	2.4	3
760	Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 475-480.	2.2	3
761	Microbiome, probiotics and dermatology. <i>British Journal of Dermatology</i> , 2019, 182, 8-9.	1.5	3
762	Assessing Efficacy and the Speed of Response in Psoriasis Treatment. <i>Journal of Dermatological Treatment</i> , 2019, 30, 523-524.	2.2	3
763	A new spin on improving adherence. <i>Journal of Dermatological Treatment</i> , 2019, 30, 631-632.	2.2	3
764	Sociodemographic factors do not have a large influence on adherence to topical treatment in patients with psoriasis. <i>British Journal of Dermatology</i> , 2019, 181, 381-382.	1.5	3
765	Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients. <i>Skin Appendage Disorders</i> , 2019, 5, 366-369.	1.0	3
766	Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 157-163.	1.2	3
767	Allergic Contact Dermatitis Secondary to Moisturizers. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 350-359.	1.2	3
768	The importance of publications, research, volunteer, and work experience in dermatology residency applicants. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e99-e100.	1.2	3
769	Do increased risks of cancer mean we need to change our approach to treatment?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 1-2.	2.2	3
770	Frequency of procedural and medical treatments of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 916-918.	1.2	3
771	Impact of the COVID-19 pandemic on dermatology departments' support of medical students: A survey study. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	3
772	Morgellons disease etiology and therapeutic approach: a systematic review. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	3
773	Understanding views of patients on biologics for psoriasis amid the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e249-e251.	2.4	3
774	Is Dupilumab an Immunosuppressant?. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 209-210.	0.8	3

#	ARTICLE	IF	CITATIONS
775	Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study. <i>British Journal of Dermatology</i> , 2022, 187, 250-251.	1.5	3
776	Erythema ab igne: evolving technology, evolving presentation. <i>Dermatology Online Journal</i> , 2014, 20, .	0.5	3
777	Costs of Common Psoriasis Medications, 2010-2014. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 305-8.	0.8	3
778	Topical corticosteroids for treatment-resistant atopic dermatitis. <i>Cutis</i> , 2018, 102, 205-209.	0.3	3
779	Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	3
780	Two cases of mycosis fungoides diagnosed after treatment non-response to dupilumab. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	3
781	Accountability in reminder-based adherence interventions: A review. <i>Patient Education and Counseling</i> , 2022, 105, 2645-2652.	2.2	3
782	Immunohistochemical localization of alpha 2-macroglobulin receptors in human skin. <i>Acta Dermato-Venereologica</i> , 1992, 72, 331-3.	1.3	3
783	Internet-based survey intervention improves adherence to methotrexate among psoriasis patients. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2784-2789.	2.2	3
784	Review of Tralokinumab in the Treatment of Atopic Dermatitis. <i>Annals of Pharmacotherapy</i> , 2023, 57, 333-340.	1.9	3
785	Transmittance Properties of Flurandrenolide Tape for Psoriasis: Helpful Adjunct to Phototherapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2000, 4, 196-198.	1.2	2
786	Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 361-363.	1.2	2
787	Trends in on and off-label calcipotriene use. <i>Journal of Dermatological Treatment</i> , 2006, 17, 308-313.	2.2	2
788	Prescribing on the basis of subjective disease severity. <i>Journal of Dermatological Treatment</i> , 2006, 17, 261-261.	2.2	2
789	The distress of psoriasis doesn't necessarily imply good treatment adherence: A lesson from the treatment of sexually transmitted disease. <i>Journal of Dermatological Treatment</i> , 2008, 19, 132-133.	2.2	2
790	Blistering Eruption in a Latino Migrant Farmworker. <i>Journal of Agromedicine</i> , 2008, 12, 81-85.	1.5	2
791	Optimizing topical therapy for psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 385-402.	0.3	2
792	Commentary: The relative ease of obtaining a dermatologic appointment in Boston. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 949-950.	1.2	2

#	ARTICLE	IF	CITATIONS
793	PLACEBO RESPONSE?. Psychosomatic Medicine, 2010, 72, 505.	2.0	2
794	IL-12/23 Inhibitors and Their Potential Benefits and Risks for Psoriasis Patients. Psoriasis Forum, 2010, 16a, 16-20.	0.1	2
795	Where did current academic dermatologists train?. Journal of the American Academy of Dermatology, 2010, 62, 522-523.	1.2	2
796	Monitoring psoriasis patients being treated with tumour necrosis factor inhibitors: use your judgment. British Journal of Dermatology, 2011, 165, 229-230.	1.5	2
797	Importance of Providing Adequate Patient Information to Ensure Good Adherence and Outcomes. Archives of Dermatology, 2011, 147, 695.	1.4	2
798	Practice Gap in Patient Education. Archives of Dermatology, 2012, 148, 1255.	1.4	2
799	Services Available and Their Effectiveness. Dermatologic Clinics, 2012, 30, 19-37.	1.7	2
800	Patterns of disease and treatment of cold sores. Journal of Dermatological Treatment, 2013, 24, 439-443.	2.2	2
801	Analysis of a <i>New York Times</i> Article on the Public's Perception of Dermatologists. JAMA Dermatology, 2014, 150, 695.	4.1	2
802	Improving patients' satisfaction with care. Clinics in Dermatology, 2014, 32, 444-447.	1.6	2
803	Pharmacological treatments in pregnant women with psoriasis in the U.S.A.. British Journal of Dermatology, 2015, 172, 807-810.	1.5	2
804	Oral tofacitinib for psoriasis: what happens with interrupted treatment?. British Journal of Dermatology, 2015, 172, 1194-1195.	1.5	2
805	Trends in Ambulatory Health Care Usage for Adult Acne. Journal of Cutaneous Medicine and Surgery, 2015, 19, 377-379.	1.2	2
806	Obtaining an Adequate Specimen for the Diagnosis of Pigmented Lesions. Journal of the American Board of Family Medicine, 2015, 28, 523-525.	1.5	2
807	Improved psoriasis with weight loss: the role of behavioural factors. British Journal of Dermatology, 2015, 172, 826-827.	1.5	2
808	The proliferation of online for-profit medical journals. Journal of the American Academy of Dermatology, 2016, 75, 656-657.	1.2	2
809	Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Review of Clinical Pharmacology, 2016, 9, 525-539.	3.1	2
810	Is depression screening in patients with acne critical?. British Journal of Dermatology, 2018, 179, 226-227.	1.5	2

#	ARTICLE	IF	CITATIONS
811	Comment on "Serious infections among a large cohort of subjects with systemically treated psoriasis", Journal of the American Academy of Dermatology, 2018, 78, e113-e114.	1.2	2
812	Rapid, successful treatment of atopic dermatitis recalcitrant to topical corticosteroids. Pediatric Dermatology, 2018, 35, 278-279.	0.9	2
813	Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis. Journal of Dermatological Treatment, 2018, 29, 36-38.	2.2	2
814	Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. Journal of Dermatological Treatment, 2018, 29, 32-35.	2.2	2
815	A safety review of the medications used to treat atopic dermatitis. Expert Opinion on Drug Safety, 2018, 17, 179-183.	2.4	2
816	Public Perception of Ethical Issues in Dermatology: Evidenced by New York Times Commenters. Dermatologic Surgery, 2018, 44, 1571-1577.	0.8	2
817	Satisfied patients and pediatricians: a cross-sectional analysis. Patient Related Outcome Measures, 2018, Volume 9, 299-307.	1.2	2
818	Current Psoriasis Efficacy Outcome Measures in Clinical Trials. Current Dermatology Reports, 2018, 7, 261-268.	2.1	2
819	The perceived promise of p19 inhibitors. British Journal of Dermatology, 2018, 179, 556-557.	1.5	2
820	Benzoyl peroxide gel stains synthetic fabrics less than they stain cotton. Journal of the American Academy of Dermatology, 2018, 85, 481-482.	1.2	2
821	Patient Perceptions of Hidradenitis Suppurativa Stressors. Journal of Dermatological Treatment, 2018, 29, 429-430.	2.2	2
822	Atopic dermatitis: a look into systemic treatments and adherence considerations. Journal of Dermatological Treatment, 2018, 29, 535-535.	2.2	2
823	Dermatology nurses view on factors related to Danish psoriasis patients' adherence to topical drugs: a focus group study. Journal of Dermatological Treatment, 2019, 32, 1-6.	2.2	2
824	Treatment decisions in psoriasis. Journal of Comparative Effectiveness Research, 2019, 8, 947-949.	1.4	2
825	Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 133-142.	0.7	2
826	Manipulating mindsets to improve patient outcomes: is it ethical? Can it be avoided?. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e79-e81.	2.4	2
827	Comparing psoriasis advertisement methods with patient willingness to initiate treatment. Journal of Dermatological Treatment, 2020, 31, 626-630.	2.2	2
828	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research, 2020, 29, 369-380.	3.1	2

#	ARTICLE	IF	CITATIONS
829	Clinical recommendations made in dermatology publications are frequently not supported by adequate evidence. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-2.	2.2	2
830	Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report. , 2020, 8, e001073.		2
831	Update on IL-17 Inhibitors for Psoriasis. <i>Current Dermatology Reports</i> , 2020, 9, 339-352.	2.1	2
832	Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 221-231.	6.7	2
833	Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age. <i>Pediatric Dermatology</i> , 2021, 38, 115-118.	0.9	2
834	Mycophenolate mofetil for the treatment of cutaneous lichen planus: A retrospective case series. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1091-1094.	1.2	2
835	Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 55-63.	1.8	2
836	The next quantum leap forward? Bimekizumab for psoriasis. <i>Lancet, The</i> , 2021, 397, 446-448.	13.7	2
837	Medication therapy management in dermatology: a call to action. <i>Journal of Dermatological Treatment</i> , 2021, 32, 373-375.	2.2	2
838	Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management. <i>Biomedicines</i> , 2021, 9, 958.	3.2	2
839	Assessing the relationship between topical corticosteroid phobia and susceptibility to misinformation in patients with atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	2
840	Should the presence of psoriatic arthritis change how we manage psoriasis?. <i>Journal of Dermatological Treatment</i> , 2021, 32, 1-8.	2.2	2
841	Methotrexate for pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease) and pityriasis lichenoides chronica: a retrospective case series of 33 patients with an emphasis on outcomes. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2
842	Adherence in Atopic Dermatitis. <i>Updates in Clinical Dermatology</i> , 2020, , 75-84.	0.1	2
843	Characterizing dermatology mobile applications that use artificial intelligence. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	2
844	Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	2
845	Adherence to levetiracetam for management of epilepsy: Assessment with electronic monitors. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 93, 51-57.	2.0	2
846	Management of Residual Psoriasis in Patients on Biologic Treatment. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 188-194.	0.8	2



#	ARTICLE	IF	CITATIONS
847	Demographics and the perceived severity of psoriasis symptoms, effect on daily life, and willingness to seek medical attention. <i>JAAD International</i> , 2020, 1, 43-45.	2.2	2
848	The impact of demographic and socioeconomic status on patient perception of barriers to outpatient dermatologic care. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 864-865.	1.2	2
849	Review of the holistic management of pediatric atopic dermatitis. <i>European Journal of Pediatrics</i> , 2022, 181, 1363-1370.	2.7	2
850	Fluconazole treatment of cutaneous cryptococcosis. <i>Archives of Dermatology</i> , 1992, 128, 1045-6.	1.4	2
851	Bullous dermatoses associated with systemic disease. <i>Dermatologic Clinics</i> , 1993, 11, 597-609.	1.7	2
852	Increasing adherence to topical therapy in psoriasis through use of solution medication. <i>Dermatology Online Journal</i> , 2016, 22, .	0.5	2
853	Characterization of Patients' Quality of Life and Experience in the Course of Acne Treatment. <i>Skinmed</i> , 2017, 15, 431-435.	0.0	2
854	Adherence to topical treatment can improve treatment-resistant moderate psoriasis. <i>Cutis</i> , 2020, 105, 89-91;E2;E3.	0.3	2
855	Digital future of dermatology. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	2
856	An overview of benvitimod for the treatment of psoriasis: a narrative review. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 327-333.	1.8	2
857	Greater rosacea severity correlates with greater adherence and improvement in a clinical study. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	1.2	2
858	Methotrexate for Cutaneous Sarcoidosis: A Dermatology-Based Case Series of 23 Patients. <i>Journal of Cutaneous Medicine and Surgery</i> , 0, , 120347542211013.	1.2	2
859	Editorial. <i>Journal of Dermatological Treatment</i> , 2003, 14, 198-199.	2.2	1
860	Patients Spend More Time With the Physician for Excision of a Malignant Skin Lesion Than for Excision of a Benign Skin Lesion. <i>Dermatologic Surgery</i> , 2004, 30, 351-354.	0.8	1
861	Cyclosporin in psoriasis: how?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 250-253.	2.4	1
862	Infliximab for inpatient psoriasis management “is there a role?”. <i>Journal of Dermatological Treatment</i> , 2005, 16, 314-318.	2.2	1
863	Health insurance benefit limits: General concepts and the potential impact on dermatologic treatment. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 140-142.	1.2	1
864	Treatment Patterns and Cost of Nonmelanoma Skin Cancer Management. <i>Dermatologic Surgery</i> , 2006, 32, 1266-1271.	0.8	1

#	ARTICLE	IF	CITATIONS
865	Intermittent dosing of biologics for psoriasis. <i>Journal of Dermatological Treatment</i> , 2006, 17, 5-5.	2.2	1
866	Why don't patients get better? The three "nons". <i>Journal of Dermatological Treatment</i> , 2007, 18, 136-137.	2.2	1
867	What you should do when people don't get well. <i>Journal of Dermatological Treatment</i> , 2007, 18, 196-196.	2.2	1
868	The importance of avoiding electrosurgical artifact at the margins of melanoma excisions. <i>Journal of Surgical Oncology</i> , 2007, 96, 637-638.	1.7	1
869	Adherence must always be considered: Is everolimus really ineffective as a treatment for atopic dermatitis?. <i>Journal of Dermatological Treatment</i> , 2009, 20, 317-318.	2.2	1
870	Radiofrequency heating for striae: Does it work?. <i>Journal of Dermatological Treatment</i> , 2009, 20, 318-318.	2.2	1
871	Tattooing practices in the migrant Latino farmworker population: risk for blood-borne disease. <i>International Journal of Dermatology</i> , 2009, 48, 1400-1402.	1.0	1
872	Commentary on "Indoor tanning injuries: an evaluation of FDA adverse event reporting data". <i>Photodermatology Photoimmunology and Photomedicine</i> , 2009, 25, 221-222.	1.5	1
873	The prime directive for enhancing patients' medical experience. <i>Journal of Dermatological Treatment</i> , 2010, 21, 217-217.	2.2	1
874	Dermatological patient safety: Problems and solutions. <i>Journal of Dermatological Treatment</i> , 2010, 21, 86-92.	2.2	1
875	Perhaps programs are a better way to go. <i>Journal of Dermatological Treatment</i> , 2010, 21, 325-325.	2.2	1
876	Psoralen plus ultraviolet A light phototherapy effectiveness. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 718.	1.2	1
877	Seasonal variations in dermatology manuscript submission. <i>Journal of Dermatological Treatment</i> , 2011, 22, 60-60.	2.2	1
878	Let's not presuppose that patients take their medications. <i>Journal of Dermatological Treatment</i> , 2012, 23, 317-317.	2.2	1
879	Commentary: We Know How Much Mohs Is Done, but Is It Appropriate?. <i>Dermatologic Surgery</i> , 2012, 38, 1435-1436.	0.8	1
880	Calcipotriene foam, 0.005% in mild-to-moderate plaque psoriasis. <i>Expert Review of Dermatology</i> , 2012, 7, 17-26.	0.3	1
881	Decreasing frequency of office visits on fridays. <i>Journal of Dermatological Treatment</i> , 2013, 24, 405-407.	2.2	1
882	Prevalence of Psoriasis and Rosacea Comorbidities in the Outpatient Setting. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 295-298.	1.2	1

#	ARTICLE	IF	CITATIONS
883	Treatment failure of patients using topical acne treatments: an observational retrospective cohort study. <i>Journal of Dermatological Treatment</i> , 2014, 25, 193-195.	2.2	1
884	A Review of Localized Office and Home Devices in the Treatment of Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 2, 22-30.	0.7	1
885	Reply to: "Comment on "Review of patient registries in dermatology"™". <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e243.	1.2	1
886	Advances in and hope for the treatment of parasitosis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 197-197.	2.2	1
887	Adherence to topical treatments for actinic keratosis. <i>British Journal of Dermatology</i> , 2016, 175, 872-872.	1.5	1
888	TNF Inhibitors for Psoriasis and Psoriatic Arthritis. <i>Current Dermatology Reports</i> , 2017, 6, 113-120.	2.1	1
889	Perspectives. <i>Journal of Dermatological Treatment</i> , 2017, 28, 373-373.	2.2	1
890	Participating in trials can inform better clinical practice. <i>British Journal of Dermatology</i> , 2017, 177, 1148-1149.	1.5	1
891	It may not be time to clean out the sample closets. <i>Journal of Dermatological Treatment</i> , 2018, 29, 1-2.	2.2	1
892	Patient Costs Associated with Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, 167-170.	1.7	1
893	Complexities of Rosacea. <i>Dermatologic Clinics</i> , 2018, 36, xiii.	1.7	1
894	PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS'™ TREATMENT CHOICE: A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US. <i>Value in Health</i> , 2018, 21, S434-S435.	0.3	1
895	Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 931-939.	4.1	1
896	Future Therapeutics in Psoriasis. <i>Updates in Clinical Dermatology</i> , 2018, , 93-112.	0.1	1
897	Rates of psoriasis in patients with palmoplantar pustulosis. <i>British Journal of Dermatology</i> , 2019, 181, 887-888.	1.5	1
898	PBI34 PREDICTIVE VALUE OF EARLY PASI RESPONSE TO TILDRAKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS. <i>Value in Health</i> , 2019, 22, S53.	0.3	1
899	Review of Outcome Measures in Trials and Practice for Psoriasis. <i>Current Dermatology Reports</i> , 2019, 8, 313-318.	2.1	1
900	Update on Tildrakizumab for Psoriasis. <i>Current Dermatology Reports</i> , 2019, 8, 319-325.	2.1	1

#	ARTICLE	IF	CITATIONS
901	Lead with your gut: researchâ€implicated infant gut staphylococcal strains may predict development of atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 180, 1296-1297.	1.5	1
902	<p>Treatment-resistant prurigo nodularis</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2019, Volume 12, 345-346.	1.8	1
903	Engagement can increase patient willingness to take medications. <i>British Journal of Dermatology</i> , 2019, 181, 408-409.	1.5	1
904	Biologics monitoring: incongruity between recommendations and clinician monitoring trends. <i>Journal of Dermatological Treatment</i> , 2020, 31, 450-451.	2.2	1
905	Assessing perceived adverse effects of biologic medications for patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 766-768.	1.2	1
906	Optimizing presentation of expected treatment outcomes. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 602-604.	1.2	1
907	Dermatology Life Quality Index: does improving the instrument make it better?. <i>British Journal of Dermatology</i> , 2020, 182, 1082-1083.	1.5	1
908	International collaboration. <i>Journal of Dermatological Treatment</i> , 2020, 31, 757-757.	2.2	1
909	The bandwagon effect increases acne treatment willingness in teenagers. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1172-1174.	1.2	1
910	Efficacy of Applicator Devices for Self-Application of Topicals to the Back. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 249-252.	1.2	1
911	Efficacious psoriasis treatment improves patients' work productivity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e593-e596.	2.4	1
912	Evaluation of Accountability Measurement Tool in Patients with Psoriasis: A Validation Study. <i>Dermatology and Therapy</i> , 2020, 10, 495-502.	3.0	1
913	PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines. <i>Annals of Pharmacotherapy</i> , 2021, 55, 354-361.	1.9	1
914	Caregiver Preferences for the Treatment of Childhood Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 336-338.	1.2	1
915	Speed of Psoriasis Treatment Response for Biologic Agents: A Review of Phase III Clinical Trials. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 99-105.	0.7	1
916	Topical calcipotriol plus betamethasone dipropionate for the treatment of plaque psoriasis: a drug evaluation. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1107-1118.	1.8	1
917	Confidence in Biosimilar Drugs is Not Much Improved by Framing Them as the â€œGoldâ€Alternative Treatment Option to Bio-originators. <i>Dermatology and Therapy</i> , 2021, 11, 1409-1413.	3.0	1
918	An mHealth App to Support Patients With Psoriasis in Relation to Follow-up Consultations: Qualitative Study. <i>JMIR Dermatology</i> , 2021, 4, e28882.	0.7	1

#	ARTICLE	IF	CITATIONS
919	Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2021, 6, 170-173.	0.7	1
920	A wealth of new topicals for Atopic Dermatitis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 575-575.	2.2	1
921	Psoriasis comorbidities and clinical implications when using biologics. <i>Dermatological Reviews</i> , 0, , .	0.5	1
922	Measuring Adherence in Clinical Trials. , 2016, , 53-59.		1
923	Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1525-1533.	1.8	1
924	Psychological Techniques to Promote Adherence. <i>Updates in Clinical Dermatology</i> , 2020, , 29-39.	0.1	1
925	Adherence in Psoriasis. <i>Updates in Clinical Dermatology</i> , 2020, , 59-74.	0.1	1
926	Reasons for Nonadherence. <i>Updates in Clinical Dermatology</i> , 2020, , 1-11.	0.1	1
927	Time Intervals Until the First Return Office Visit After New Medications. <i>Journal of Drugs in Dermatology</i> , 2020, 19, 1226-1230.	0.8	1
928	Choosing the appropriate pharmacotherapy for Morgellons disease: an expert perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 527-530.	1.8	1
929	The presence of accountability in digital interventions targeting non-adherence: A review. <i>Patient Education and Counseling</i> , 2022, , .	2.2	1
930	Tazarotene 0.045% Lotion: A Novel Retinoid Formulation. <i>Annals of Pharmacotherapy</i> , 2022, , 106002802110721.	1.9	1
931	Atopic Dermatitis and Psoriasis are Diagnosed Clinically and Treated Empirically. <i>Dermatology and Therapy</i> , 2022, 12, 611-614.	3.0	1
932	The role of topical therapy for patients with extensive psoriasis. <i>Cutis</i> , 2007, 79, 18-31.	0.3	1
933	Common reasons why acne patients call the office. <i>Dermatology Online Journal</i> , 2014, 20, 22609.	0.5	1
934	Home ultraviolet light therapy for psoriasis: why patients choose other options. <i>Dermatology Online Journal</i> , 2014, 21, .	0.5	1
935	Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. <i>Dermatology Online Journal</i> , 2015, 21, .	0.5	1
936	First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. <i>Skinmed</i> , 2016, 14, 266-272.	0.0	1

#	ARTICLE	IF	CITATIONS
937	Presenting treatment safety data: subjective interpretations of objective information. <i>Cutis</i> , 2016, 98, 259-262.	0.3	1
938	ProvenCare-Psoriasis: A disease management model to optimize care. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
939	Addressing public criticism: a potential HIPAA violation. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
940	Morgellons disease: insights into treatment. <i>Dermatology Online Journal</i> , 2018, 24, .	0.5	1
941	Cutaneous manifestations of genodermatoses and primary immunodeficiency. <i>Dermatology Online Journal</i> , 2019, 25, .	0.5	1
942	Publication rates on the topic of racial and ethnic diversity in dermatology versus other specialties. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	1
943	Advertising techniques increase biologic treatment willingness in patients with psoriasis. <i>Dermatology Online Journal</i> , 2020, 26, .	0.5	1
944	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. <i>EMJ Dermatology</i> , 0, , 106-121.	0.0	1
945	Dermatologic management of ocular mucous membrane (cicatrical) pemphigoid with mycophenolate mofetil in 38 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	1
946	Strategies to Optimize Adherence in Patients with Mycosis Fungoides. <i>Cells</i> , 2022, 11, 113.	4.1	1
947	Impact of Unit-Dosing of Sunscreen on Adherence at Golf Tournaments. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 528-529.	1.2	1
948	Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1439-1441.	3.1	1
949	Patients who feel more accountable are more adherent: A clinical study in patients with xerosis. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 481-483.	1.2	1
950	Regarding Malpractice Claims. <i>Dermatologic Surgery</i> , 1999, 25, 737-738.	0.8	0
951	Clinical Trial Size and Efficacy. <i>Dermatologic Surgery</i> , 1999, 25, 670-671.	0.8	0
952	Use of Transcutaneous Nerve Stimulation Wristband to Treat Methotrexate-Induced Nausea. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 551-553.	1.2	0
953	Editorial. <i>Journal of Dermatological Treatment</i> , 2004, 15, 71-71.	2.2	0
954	The Touch of a Helping Hand. <i>Journal of Dermatological Treatment</i> , 2005, 16, 9-9.	2.2	0

#	ARTICLE	IF	CITATIONS
955	We need more cross-disciplinary communication. <i>Journal of Dermatological Treatment</i> , 2005, 16, 257-257.	2.2	0
956	A reappraisal of the concept of suppressive versus remittive psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2005, 16, 171-174.	2.2	0
957	Dictation templates improve coding accuracy in an academic dermatology practice. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 539-540.	1.2	0
958	Misunderstandings. <i>Journal of Dermatological Treatment</i> , 2007, 18, 4-4.	2.2	0
959	A Randomized, Double-Blind, Vehicle-Controlled, Right/Left Comparative Study of the Efficacy of Acitretin with and without the Co-Administration of 0.1% Tacrolimus Topical Ointment in the Treatment of Moderate to Severe Psoriasis. <i>Psoriasis Forum</i> , 2007, 13a, 16-20.	0.1	0
960	Reply: Interleukin-12, interleukin-23, and psoriasis: ABT-874 in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1083.	1.2	0
961	Editorial: Mental Health and Psoriasis. <i>Psoriasis Forum</i> , 2008, 14a, 8-9.	0.1	0
962	Safety and Efficacy of 16 Weeks of 30 mg/Week Intramuscular Alefacept in the Treatment of Chronic Plaque Psoriasis. <i>Psoriasis Forum</i> , 2008, 14a, 10-13.	0.1	0
963	Severity levels in psoriasis: A separate "very severe" category not required. <i>Journal of Dermatological Treatment</i> , 2009, 20, 48-51.	2.2	0
964	Many new options for improving patients' care. <i>Journal of Dermatological Treatment</i> , 2009, 20, 185-185.	2.2	0
965	Dermpath@: a professional electronic mailing list for dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 814-818.	1.3	0
966	Access to Unused Health Care. <i>Southern Medical Journal</i> , 2010, 103, 496.	0.7	0
967	Commentary: Pitfalls of Frozen Section Biopsy. <i>Dermatologic Surgery</i> , 2010, 36, 1116-1117.	0.8	0
968	Cause-specific mortality in patients with severe psoriasis. <i>British Journal of Dermatology</i> , 2010, 163, 449-449.	1.5	0
969	A Review of the Efficacy and Safety of Combined Methotrexate and Ultraviolet B Phototherapy versus Ultraviolet B Phototherapy Alone in the Treatment of Psoriasis. <i>Psoriasis Forum</i> , 2010, 16a, 26-32.	0.1	0
970	Psoriasis Regimens. , 0, , 507-513.		0
971	Simple means to enhance patients' perceptions of their physicians. <i>Journal of Dermatological Treatment</i> , 2010, 21, 61-61.	2.2	0
972	Linear hyperpigmented lesions in an 8-year-old girl. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e109.	1.2	0

#	ARTICLE	IF	CITATIONS
973	Hyperkeratotic plaques on the hands. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, e95.	1.2	0
974	Nondermatologist physicians advertising the provision of skin care services. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e111-e112.	1.2	0
975	Painful skin after sun exposure in a healthy child. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, e141.	1.2	0
976	A consideration when interpreting outpatient data. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1180-1181.	1.2	0
977	Psoriasis Patientâ€™Physician Interactions. <i>Psoriasis Forum</i> , 2011, 17a, 298-302.	0.1	0
978	It isn't a perfect world. <i>Journal of Dermatological Treatment</i> , 2011, 22, 1-1.	2.2	0
979	Usage of complementary and alternative medicine for management of skin disease. <i>Journal of Dermatological Treatment</i> , 2011, 22, 306-308.	2.2	0
980	Reaching for better understanding across the globe. <i>Journal of Dermatological Treatment</i> , 2012, 23, 397-397.	2.2	0
981	Medications Used for Acne Vulgaris: Practice Trends and the Use of Topical Combination Products. <i>Combination Products in Therapy</i> , 2012, 2, 1.	1.1	0
982	A young boy with a perioral eruption. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e159.	1.2	0
983	Patients are often terrified of treatments. <i>Journal of Dermatological Treatment</i> , 2013, 24, 81-81.	2.2	0
984	Commentary: The Growing Skin Cancer Problem. <i>Dermatologic Surgery</i> , 2013, 39, 603-604.	0.8	0
985	Commentary on â€œSafety and Efficacy of Combining Biologic with Nonbiologic Therapies for Moderate to Severe Psoriasisâ€. <i>Psoriasis Forum</i> , 2014, 20a, 150-151.	0.1	0
986	Interleukin-17 in Atherosclerosis: Commentary. <i>Psoriasis Forum</i> , 2014, 20a, 59-59.	0.1	0
987	Are patients willing to participate in surveys?. <i>Journal of Dermatological Treatment</i> , 2014, 25, 365-366.	2.2	0
988	A painful eruption on the hands of a young man. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e25-e26.	1.2	0
989	DERM: Dermatologic Education Reinforced Mnemonically. <i>Journal of Dermatological Treatment</i> , 2015, 26, 491-492.	2.2	0
990	How to manage the mother of all treatment refusal. <i>Journal of Dermatological Treatment</i> , 2015, 26, 395-395.	2.2	0



#	ARTICLE	IF	CITATIONS
991	Primary Nonadherence in Acne Treatmentâ€”Reply. JAMA Dermatology, 2015, 151, 1145.	4.1	0
992	Clinical potential of brodalumab in the management of psoriasis: the evidence to date. Psoriasis: Targets and Therapy, 2015, 5, 35.	2.2	0
993	Effect of frequency on entrance and propagation pattern of highâ€”frequency (radiofrequency) electrical currents in biologic tissues. Skin Research and Technology, 2015, 21, 291-294.	1.6	0
994	Modifying a 30-gauge needle as a hook for hard-to-access biopsy sites. Journal of the American Academy of Dermatology, 2015, 73, e183-e184.	1.2	0
995	How often do pharmacology textbooks address medication adherence?. Journal of Dermatological Treatment, 2015, 26, 199-201.	2.2	0
996	Ultraviolet B Phototherapy. , 2016, , 17-25.		0
997	Apremilast. , 2016, , 75-82.		0
998	Online Reviews of Physiciansâ€”Reply. JAMA Dermatology, 2016, 152, 350.	4.1	0
999	Evolution in psoriasis management. Journal of Dermatological Treatment, 2017, 28, 187-187.	2.2	0
1000	Reply to: â€œels treatment of acne as simple as encouraging primary care physicians to prescribe more retinoids?â€” Journal of the American Academy of Dermatology, 2017, 76, e39.	1.2	0
1001	Implications of treatment resistant severe psoriasis for benchmarking quality of care. Journal of Dermatological Treatment, 2017, 28, 475-475.	2.2	0
1002	Rethinking the costs of psoriasis management. Journal of Dermatological Treatment, 2017, 28, 573-573.	2.2	0
1003	Yet another step forward!. British Journal of Dermatology, 2018, 178, 22-22.	1.5	0
1004	Compliance and Persistency. , 2018, , 37-49.		0
1005	4-Day evaluation of the irritation potential of topical desoximetasone 0.25% and 0.05% spray on light-exposed skin. Journal of Dermatological Treatment, 2018, 29, 415-417.	2.2	0
1006	Six week evaluation of the potential for topical desoximetasone 0.25% spray to induce photoallergic skin reaction. Journal of Dermatological Treatment, 2018, 29, 269-271.	2.2	0
1007	A Pilot Study Characterizing Factors in Adherence to Cutaneous Lupus Treatment. Journal of Cutaneous Medicine and Surgery, 2018, 22, 530-532.	1.2	0
1008	Psoriasis in Skin of Color. , 2018, , 241-250.		0

#	ARTICLE	IF	CITATIONS
1009	Pilot study of the feasibility of a double-blind, randomized, placebo-controlled localized area ultraviolet phototherapy trial methodology. <i>Skin Research and Technology</i> , 2019, 25, 103-105.	1.6	0
1010	Modulating Patient Perception of Systemic Psoriasis Treatment Risk. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 143-146.	0.7	0
1011	The complexity of adverse event assessment and counseling for patients on biologic treatment. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 809-811.	3.0	0
1012	PBI30 BUDGET-IMPACT AND COST-EFFECTIVENESS OF TILDRAKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS FROM A US HEALTH PLAN PERSPECTIVE. <i>Value in Health</i> , 2019, 22, S52.	0.3	0
1013	PBI38 TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY METABOLIC SYNDROME STATUS. <i>Value in Health</i> , 2019, 22, S54.	0.3	0
1014	PBI41 TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY PSORIATIC ARTHRITIS STATUS. <i>Value in Health</i> , 2019, 22, S55.	0.3	0
1015	Publication productivity of authors of psoriasis clinical practice guidelines with and without ties to industry. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1432-1433.	1.2	0
1016	An Evidence-Based Evaluation of Disclosure. <i>Journal of Dermatological Treatment</i> , 2019, 30, 423-423.	2.2	0
1017	Can We Tell Patients That IL-23 and TNF- $\alpha$ Inhibition Are "Natural" Ways to Treat Psoriasis?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 337-338.	1.2	0
1018	Choice Overload in Systemic Psoriasis Therapy. <i>Journal of Dermatological Treatment</i> , 2019, 30, 103-104.	2.2	0
1019	Rosacea Severity Assessment: Review of Evaluation Methods Used in Clinical Trials. , 2019, , 1-14.		0
1020	Use of absolute risk measurements in observational dermatology studies: important information for decision-making is frequently absent. <i>British Journal of Dermatology</i> , 2019, 180, 678-679.	1.5	0
1021	Heterogeneity and variation of innovator biologics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e161-e163.	2.4	0
1022	Our ambition in a changing landscape of psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2020, 31, 105-107.	2.2	0
1023	A hands-off approach may be more successful in treating chronic hand eczema. <i>British Journal of Dermatology</i> , 2020, 182, 1078-1078.	1.5	0
1024	Commentary on Surgical Volume of Dermatologists Who Do Not Perform Mohs Micrographic Dermatologic Surgery. <i>Dermatologic Surgery</i> , 2020, 46, 7-8.	0.8	0
1025	Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 174-177.	0.7	0
1026	A rare case of anal squamous cell carcinoma metastasizing to the scrotum. <i>JAAD Case Reports</i> , 2020, 6, 743-746.	0.8	0

#	ARTICLE	IF	CITATIONS
1027	Balancing rules with common sense in the protection of human subjects. Journal of Dermatological Treatment, 2020, 31, 661-661.	2.2	0
1028	An Analysis of the Perception of Psoriasis Symptoms and the Impact on Willingness to Seek Medical Attention. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 109-113.	0.7	0
1029	A hyperkeratotic drug reaction in a patient on antiretroviral therapy. JAAD Case Reports, 2020, 6, 1239-1241.	0.8	0
1030	Do increased risks of cancer mean we need to change our approach to treatment?. Journal of Dermatological Treatment, 2020, , 1-4.	2.2	0
1031	Trends in the Demographics and Treatment of Prurigo Nodularis in the United States. Journal of Cutaneous Medicine and Surgery, 2020, 24, 531-533.	1.2	0
1032	Medications in dermatology are safer and more efficient than they used to be. Expert Opinion on Drug Safety, 2020, 19, 359-360.	2.4	0
1033	Dermatological disorders. , 2020, , 355-377.		0
1034	Adherence to Drug Therapy. , 2021, , 34-39.e1.		0
1035	Long-term efficacy of certolizumab pegol for psoriasis. British Journal of Dermatology, 2021, 184, 588-589.	1.5	0
1036	Evidence is lacking for or against palmoplantar pustulosis treatments: what does this mean for the clinician. British Journal of Dermatology, 2021, 184, 990-990.	1.5	0
1037	Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older. Expert Opinion on Pharmacotherapy, 2021, 22, 543-547.	1.8	0
1038	Reply to Letter to the Editor. Journal of the American Academy of Dermatology, 2021, 84, e111-e112.	1.2	0
1039	Treating a chronic disease without chronic adherence. Journal of Dermatological Treatment, 2021, 32, 131-131.	2.2	0
1040	Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm. Annals of Pharmacotherapy, 2021, 55, 1297-1299.	1.9	0
1041	Tildrakizumab: interpreting the data. British Journal of Dermatology, 2021, 185, 242-243.	1.5	0
1042	The effect of physician appearance on patient perceptions of treatment plans. Dermatology Online Journal, 2021, 27, .	0.5	0
1043	Studies of single and multiple institutions may illustrate different treatment practices for psoriasis. Journal of the American Academy of Dermatology, 2021, 85, e51-e52.	1.2	0
1044	How should medical students prepare for a clinical dermatology rotation?. Dermatology Online Journal, 2021, 27, .	0.5	0

#	ARTICLE	IF	CITATIONS
1045	Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic". Journal of the American Academy of Dermatology, 2021, 85, e321.	1.2	0
1046	A narrative review of systematic reviews on adherence to psoriasis treatments. Dermatological Reviews, 0, , .	0.5	0
1047	The relative weak way and the absolute strong way to communicate risk information. Journal of Dermatological Treatment, 2021, , 1-3.	2.2	0
1048	Management of Psoriasis. Southern Medical Journal, 2009, 102, 631-636.	0.7	0
1049	Summary of Published Treatment Guidelines. , 2014, , 301-313.		0
1050	Hyperkeratotic Eczema (Psoriasis) of the Palms. , 2014, , 139-147.		0
1051	Commentary on "Gynecomastia: Etiologies, Clinical Presentations, Diagnosis, and Management". Southern Medical Journal, 2014, 107, 50-51.	0.7	0
1052	Moving Away from Fee-for-Service: Implications for Medication Adherence. Southern Medical Journal, 2015, 108, 298-299.	0.7	0
1053	Adherence in Acne. , 2016, , 77-99.		0
1054	Optimizing the Physician-Patient Relationship and Educating the Patient About Adherence. , 2016, , 143-150.		0
1055	Choosing the Treatment the Patient Is Most Likely To Use. , 2016, , 151-162.		0
1056	Tumid lupus erythematosus and systemic lupus erythematosus: a rare coexistence. BMJ Case Reports, 2021, 14, e245196.	0.5	0
1057	Why aren't they using their medicine?. Pediatric Dermatology, 2020, 37, 62-63.	0.9	0
1058	Adherence in Pediatric Populations. Updates in Clinical Dermatology, 2020, , 41-50.	0.1	0
1059	Utilization of an Online Cash-Pay Pharmacy for Topical 5-Fluorouracil Prescriptions in Older Patients. Journal of Drugs in Dermatology, 2020, 19, 539-542.	0.8	0
1060	Anecdote Increases Patient Willingness to Take a Biologic Medication for Psoriasis. , 2021, 108, 20-24.		0
1061	Secukinumab treatment and vaccination efficacy. Clinical and Experimental Dermatology, 2021, , .	1.3	0
1062	Demographics and the perception of psoriasis therapy adverse effects and treatment preference: A cross-sectional survey of a convenience sample of people with psoriasis. JAAD International, 2020, 1, 59-61.	2.2	0

#	ARTICLE	IF	CITATIONS
1063	Assessing the effect of demographic background on willingness to initiate a biologic. JAAD International, 2020, 1, 46-47.	2.2	0
1064	Summary of Published Treatment Guidelines. , 2021, , 399-414.		0
1065	The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab. American Health and Drug Benefits, 2019, 12, 22-26.	0.5	0
1066	Developing electronic monitor adapters for dermatologic medication containers: A methods paper. Skin Research and Technology, 2022, 28, 371-373.	1.6	0
1067	Tacrolimus œswish and spitœfor complex aphthosis: outcomes in 21 patients. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
1068	Looking beyond the borders of our specialty: the 2006 Clarence S. Livingood MD Lecture. Dermatology Online Journal, 2007, 13, 20.	0.5	0
1069	Photographic assessment of tretinoin microsphere gel in moderate acne. Journal of Drugs in Dermatology, 2008, 7, s19-24.	0.8	0
1070	Regulating off-label promotion of medications: has the pendulum swung too far?. Skin Therapy Letter, 2015, 20, 1-4.	0.3	0
1071	A boxed warning for inadequate psoriasis treatment. Cutis, 2016, 98, 206-207.	0.3	0
1072	Cost of diagnosing psoriasis and rosacea for dermatologists versus primary care physicians. Cutis, 2017, 99, 134-136.	0.3	0
1073	Hypothyroidism in Patients with Psoriasis or Rosacea: A Large Population Study. Dermatology Online Journal, 2016, 22, .	0.5	0
1074	Hyperpigmented Patches on the Dorsal Hands. American Family Physician, 2018, 97, 603-604.	0.1	0
1075	Automobile injury: a common familiar risk for presenting and comparing risks in dermatology. Cutis, 2018, 102, 416-420.	0.3	0
1076	Strategies to reduce youth indoor tanning injuries. Cutis, 2018, 102, 383-384.	0.3	0
1077	Photodamage spares the distal digits owing to primate-like hand flexion. Dermatology Online Journal, 2019, 25, .	0.5	0
1078	Clinical case-viewing sessions in dermatology: the patient perspective. Cutis, 2020, 105, 200-201.	0.3	0
1079	Safe Step Act: does it undermine step therapy?. Dermatology Online Journal, 2020, 26, .	0.5	0
1080	Patients use more topical medication when the medications come in a larger container. Dermatology Online Journal, 2020, 26, .	0.5	0

#	ARTICLE	IF	CITATIONS
1081	Saccharomyces cerevisiae as a skin physiology, pathology, and treatment model. Dermatology Online Journal, 2020, 26, .	0.5	0
1082	Assessing the utility of the decoy effect on biologic treatment preference. Dermatology Online Journal, 2021, 27, .	0.5	0
1083	Views and Beliefs of Vitiligo Patients in Online Discussion Forums: A Qualitative Study. , 2022, 109, 49-53.		0
1084	Percutaneous egression: What do we know?. Skin Pharmacology and Physiology, 2022, , .	2.5	0
1085	Typical Scurvy in an Atypical Patient: Case Report. SN Comprehensive Clinical Medicine, 2022, 4, .	0.6	0
1086	Assessing adults' beliefs about the motivations for indoor tanning. Photodermatology Photoimmunology and Photomedicine, 2023, 39, 66-68.	1.5	0
1087	Patient willingness to receive full-body skin exams based on the sex and/or gender and training level of provider: a survey study. Clinical and Experimental Dermatology, 2022, , .	1.3	0
1088	The Role of Anticipation in Patient Adherence. Southern Medical Journal, 2022, 115, 315-316.	0.7	0
1089	Adherence to drug therapy. , 2013, , 34-39.e1.		0
1090	Hand Dermatitis Secondary to Exposure to Butternut Squash. Case Reports in Dermatology, 0, , 123-126.	0.8	0
1091	Fear of Negative Evaluation in Hidradenitis Suppurativa Patients is Correlated with Worse Quality of Life: An Observational Study. British Journal of Dermatology, 0, , .	1.5	0
1092	Review of Calcipotriene and Betamethasone Dipropionate Cream in the Treatment of Psoriasis. Annals of Pharmacotherapy, 0, , 106002802211055.	1.9	0